Podcasts about PubMed

Can you really trust the science behind fitness and wellness? On this episode of the “NASM-CPT Podcast,” host, and NASM Master Instructor, Rick Richey, dives deep into the world of peer reviewed scientific research—unpacking what it is, how it's done, and why it matters for anyone serious about health, fitness, and personal training. Is all research created equal? Are randomized controlled trials really the “gold standard”? And just who are these so-called “peers” deciding what gets published and what doesn't? Rick takes you behind the scenes of the research process: from journals and methodology to the rigorous checks that keep scientists honest. He even shares a personal story about making a mistake in his own dissertation—revealing how errors get caught, what happens next, and why transparency is essential. Wondering if you can trust resources like PubMed, or curious if your favorite strength & conditioning principles are truly evidence-based? This episode delivers clear, honest answers. Perfect for trainers, fitness enthusiasts, and anyone who's ever wondered if they should believe the latest “groundbreaking” study, this conversation arms you with the tools to spot reliable science, identify real experts, and see through the flashy fads on social media. Hit play to discover if peer reviewed research really deserves your trust—and why critical thinking is your best fitness companion. Subscribe, rate, and share for more science-backed insight from the front lines of exercise science! If you like what you just consumed, leave us a 5-star review, and share this episode with a friend to help grow our NASM health and wellness community! The content shared in this podcast is solely for educational and entertainment purposes. It is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek out the guidance of your healthcare provider or other qualified professional. Any opinions expressed by guests and hosts are their own and do not necessarily reflect the views of NASM. Introducing NASM One, the membership for trainers and coaches. For just $35/mo., get unlimited access to over 300 continuing education courses, 50% off additional certifications and specializations, EDGE Trainer Pro all-in-one coaching app to grow your business, unlimited exam attempts and select waived fees. Stay on top of your game and ahead of the curve as a fitness professional with NASM One. Click here to learn more. ttps://bit.ly/4ddsgrm

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry takes us behind the scenes into the dynamic world of research and curriculum development in the functional health space. Margaret sits down with two of Restorative Wellness Solutions' powerhouse instructors, Ellen Lovelace and Paige Reagan, for a candid conversation about the challenges, surprises, and daily realities of translating emerging science into practical, safe, and effective tools for clinicians.   In this interview, we discuss:     -Specific ways that Ellen & Paige demonstrate curriculum leadership and research support for RWS   -How to respond to new studies or challenges to existing curriculum    -How to decide which sources to trust   -How to evaluate clinical research (red & green flags)   -Addressing research limitations and gaps    -Using research tools and AI in gathering evidence   The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Ellen:  Website: www.abalancedtable.net Facebook: www.facebook.com/abalancedtable Instagram: www.instagram.com/abalancedtable   Connect with Paige: Website: www.naturallynourishedwellness.com Instagram: www.instagram.com/paigereaganntp   Timestamps: 00:00 From Russian Studies to Health Advocacy 07:56 Curriculum Accuracy and Depth Focus 12:57 Using AI for Study Validation 19:20 Evaluating Research Article Credibility 25:24 Animal Study Relevance and Limitations 28:03 "Pediatric Research Gaps in Drug Trials" 33:55 "Teaching Deepens Understanding" 41:17 Questioning AI for Balanced Answers 44:47 Effective Research Strategies and AI Limitations 52:04 Verify Before Believing Headlines 55:52 "Unpaywall: Access Free Academic Papers" 01:00:33 "The Clinician's Corner Podcast" Speaker bios: Ellen Lovelace, Lead Instructor & Curriculum Development Master RHP, MPH, FNTP, Board Certified in Holistic Nutrition® Ellen (she/her) has been actively working to educate and improve the public's health for almost 20 years. Ellen received her Masters in Public Health from The George Washington University, and went on to run everything from tuberculosis prevention programs in Russia to dental health education programs along the Texas/Mexico border. She was also the founding Executive Director of the women's health program at Stanford University. When Ellen became drawn to a more holistic model, she received her certifications as a Nutritional Therapy Consultant and a Master Restorative Health Practitioner. She is the owner of A Balanced Table Nutritional Therapy in San Jose, CA, her private functional nutrition practice. Ellen focuses on cutting through the confusion and nutrition “noise,” digging to the roots of clients' dysfunction, and figuring out the best way for them to eat, drink, and thrive. She uses the IRH functional analysis tools daily, and is excited to share her passion for these methods. Ellen believes that only by focusing on root causes, combined with whole foods nutrition, can true wellness be achieved. Ellen is also a passionate animal lover who volunteers at a wildlife rescue facility, and can often be found smelling of skunk while covered in Mastiff drool.    Paige Reagan, Instructor and Research Master RHP, FNTP Paige has spent most of her career working in Research and Development in the areas of clinical research, regulatory affairs, and medical writing. She has a wide range of experience in the therapeutic areas of cardiovascular health, pulmonary arterial hypertension, diabetes, bone health, osteoarthritis/rheumatoid arthritis, and urology, among others. Her work has contributed to numerous regulatory approvals as well as publications in major medical journals such as the New England Journal of Medicine, Lancet, Circulation, and American Heart Journal. Paige has since earned certifications as a Functional Nutritional Therapy Practitioner and Master Restorative Health Practitioner. She is owner of Naturally Nourished Wellness, a small practice specializing in gut health and the downstream effects of poor digestion. She strives to find balance between the holistic and mainstream approaches and aims to provide her clients with the best of both worlds, using her critical thinking skills from years in research combined with objective laboratory testing and her passion for the restorative power of whole foods and simple lifestyles. She spends her free time exploring the outdoors with her family, swinging kettlebells, and creating baked goods with healthier ingredients.   Keywords: functional nutrition, public health, research process, curriculum development, clinical research, regulatory affairs, medical writing, gastrointestinal healing, lab testing, food sensitivities, evidence-based practice, study design, randomized controlled trials, observational studies, animal studies, peer review, PubMed, Google Scholar, AI tools in research, ChatGPT, consensus, study citations, clinical anecdote, sample size, funding bias, meta-analysis, systematic reviews, biostatistics, clinical protocols, dietary supplements   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Neuropathyct.com1) Symptoms usually creep forward More numbness, burning, pins-and-needles, and sensitivity changes over time. (NINDS)2) Sleep gets hammered Neuropathic pain commonly disrupts sleep, which then worsens pain perception the next day. (ScienceDirect, PMC)3) Balance confidence drops; fall risk rises Loss of sensation and vibration sense increases falls and near-falls—especially in older adults. (PMC, PubMed, Frontiers)4) Foot problems can snowball (especially with diabetes) Delayed care → unnoticed injuries/ulcers → infection → higher chance of amputation if things progress. (NCBI, PMC)5) Daily function and quality of life shrink People report limits in walking, standing, hobbies, and overall well-being. Mood and anxiety often worsen. (Nature, PMC)6) Heavier reliance on pain meds without addressing nerve function Drugs like gabapentin/pregabalin/duloxetine may help pain for some, but results vary and they don't restore nerve function. (Patients should never change meds without their prescriber.) (ScienceDirect, Mayo Clinic Proceedings, PMC)7) Hidden injuries are easier to miss Reduced sensation means burns, cuts, or shoe-related wounds can go unnoticed and worsen. (This podcast welcomes your feedback here are several ways to reach out to me. If you have a topic you would like to hear about send me a message. I appreciate your listening. Dr. Brian Mc Kayhttps://twitter.com/DarienChiro/https://www.facebook.com/ChiropractorBrianMckayhttps://chiropractor-darien-dr-brian-mckay.business.sitehttps://podcasts.apple.com/us/podcast/not-just-chiropractor-for-stamford-darien-norwalk-new/id1503674397?uo=4Core Health Darien-Dr.Brian Mc Kay 551 Post RoadDarien CT 06820203-656-363641.0833695 -73.46652073GMP+87 Darien, Connecticuthttps://youtu.be/WpA__dDF0O041.0834196 -73.46423349999999https://darienchiropractor.comhttps://darienchiropractor.com/darien/darien-ct-understanding-pain/Find us on Social Mediahttps://chiropractor-darien-dr-brian-mckay.business.site https://www.youtube.com/channel/UCNHc0Hn85Iiet56oGUpX8rwhttps://docs.google.com/spreadsheets/d/1nJ9wlvg2Tne8257paDkkIBEyIz-oZZYy/edit#gid=517721981https://goo.gl/maps/js6hGWvcwHKBGCZ88https://www.youtube.com/my_videos?o=Uhttps://www.linkedin.com/in/darienchiropractorhttps://www.facebook.com/ChiropractorBrianMckayhttps://sites.google.com/view/corehealthdarien/https://sites.google.com/view/corehealthdarien/home

Sunday, September 7, 2025. Week 37. Why does CURE SYNGAP1 aka SRF matter?  Do PAGS make a difference? Heck yes. Empower Families - Support.  Educate.  Activate.  Coordinate. Use Money Catalytically - Tax advantage.  Pool.  Manage.  Make Catalytic.  Focus.  Manage. Partner with Science & Medicine - Push forward.  Connect efforts.  Focus on Tx.  Work in Clinic. Leverage Ecosystem.  Industry.  PAGs.  Superpags (CB, GG, ELF). Ensure Continuity.  Our kids will outlast us.  Our energy wanes.  Life happens.  Cure SYNGAP1 never stops focusing on the biggest challenge in our lives: SRD. Because you VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    Gala video: Look at those faces.https://www.youtube.com/watch?v=d6dCSBq27Gc   Friday: Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25   Scramble for SYNGAP October 4, 2025 - Greer, SC cureSYNGAP1.org/Scramble

Are You Using the Wrong Sized Cuff?Welcome to the Hypertension Resistant to Treatment Podcast, the #1 Hypertension Podcast in the world, with listeners from more than 152 countries who depend on our content. We are your primary resource for obtaining straightforward, practical, evidence-based information about high blood pressure management, regardless of your situation as a patient, healthcare provider, or family member. High blood pressure isn't always simple. The condition known as resistant hypertension affects many people who have high blood pressure that does not respond to medication or lifestyle changes. The medical field identifies treatment-resistant hypertension as a demanding yet vital medical condition that doctors encounter in their practice. The Hypertension Resistant to Treatment Podcast, website, and YouTube channel highlight the most challenging cases because these individuals have attempted multiple solutions without achieving any resolution. This podcast is here for them, but also for anyone touched by high blood pressure. Whether you're just starting your journey with prehypertension, you're living with long-standing hypertension, or you're a provider searching for better strategies to help your patients.The right place exists for those seeking answers, motivation, and success tools. The podcast Hypertension Resistant to Treatment presents blood pressure information in an easy-to-understand format that helps people control their condition. The Hypertension Resistant to Treatment podcast is hosted by Dr. Tonya Breaux-Shropshire, PhD, DNP, MPH, FNP-BC. Pubmed, Research Gate, UAB Alumni, and Research SymposiumFree Blood Pressure Log App without adsBest Blood Pressure Paper LogAHA Blood Pressure Paper LogSend us a text Support the showSupport the podcast by subscribing using this link: click here. We appreciate your support, thank you! Log your blood pressure and share with your provider (click here). Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research.Royalty-free music: Turn on My Swag 2 Epidemic Sound****Disclaimer: This podcast is for educational purposes only and is not medical advice. Always consult your own healthcare provider about your health. The views shared are those of the host and guests, and do not represent any other organization.”

Why Wrist Blood Pressure Monitors Could  Be Dangerous. (Watch Before You Buy!).Welcome to the Hypertension Resistant to Treatment Podcast, the #1 Hypertension Podcast in the world, with listeners from more than 152 countries who depend on our content. We are your primary resource for obtaining straightforward, practical, evidence-based information about high blood pressure management, regardless of your situation as a patient, healthcare provider, or family member. High blood pressure isn't always simple. The condition known as resistant hypertension affects many people who have high blood pressure that does not respond to medication or lifestyle changes. The medical field identifies treatment-resistant hypertension as a demanding yet vital medical condition that doctors encounter in their practice. The Hypertension Resistant to Treatment Podcast, website, and YouTube channel highlight the most challenging cases because these individuals have attempted multiple solutions without achieving any resolution. This podcast is here for them, but also for anyone touched by high blood pressure. Whether you're just starting your journey with prehypertension, you're living with long-standing hypertension, or you're a provider searching for better strategies to help your patients.The right place exists for those seeking answers, motivation, and success tools. The podcast Hypertension Resistant to Treatment presents blood pressure information in an easy-to-understand format that helps people control their condition. The Hypertension Resistant to Treatment podcast is hosted by Dr. Tonya Breaux-Shropshire, PhD, DNP, MPH, FNP-BC. Pubmed, Research Gate, UAB Alumni, and Research SymposiumFree Blood Pressure Log App without adsBest Blood Pressure Paper LogAHA Blood Pressure Paper LogSend us a text Support the showSupport the podcast by subscribing using this link: click here. We appreciate your support, thank you! Log your blood pressure and share with your provider (click here). Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research.Royalty-free music: Turn on My Swag 2 Epidemic Sound****Disclaimer: This podcast is for educational purposes only and is not medical advice. Always consult your own healthcare provider about your health. The views shared are those of the host and guests, and do not represent any other organization.”

Friday, August 29th, 2025. Week 35. 5th Annual Gala was a great success! cureSYNGAP1.org/Gala5 Sad to miss it?  Join us in Boston or South Carolina. Deadline for Boston is 9/3 for tickets. Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25 Scramble for SYNGAP October 4, 2025 - Greer, SC cureSYNGAP1.org/Scramble   SRF is active in Lisbon at #IEC2025 thank you KD, JA, VA!  Hi Dr. Knowles! We are at Booth #17 https://www.linkedin.com/posts/victoria-arteaga-26913433_syngap1-familyjourney-resilience-activity-7366951726001606657-6pcM #Bexicaserin News: New data from the PACIFIC Study, LP352-202, Open Label Extension (OLE) will be presented at the 36th International Epilepsy Congress (IEC) in Lisbon, Portugal (Aug 30 - Sept 3, 2025). The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress   Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor seizure frequency in the extension study comparable to reductions seen in the Phase 1b/2a PACIFIC trial, reinforcing durability of response and validating its progression to Phase 3 trials.   Additional data will be presented from the audiogenic seizure model and the GAERS absence epilepsy model, investigating sudden unexpected death in epilepsy (SUDEP), and seizure reduction respectively.   During the OLE, a median reduction of 59.3% in countable motor seizure frequency was observed, with 55% of participants experiencing reductions of ≥50% compared to the baseline before the PACIFIC trial.   This trial, EMERALD and other studies all at https://curesyngap1.org/resources/studies/   See and comment on Vicky's recent post on her 7 year SYNGAP1-iversary: https://www.linkedin.com/posts/victoria-arteaga-26913433_syngap1-familyjourney-resilience-activity-7366951726001606657-6pcM    Join Citizen Health, we are at 275!  We should double that. https://www.citizen.health/partners/srf   DSCIII Renewed to include SYNGAP1 alongside TSC, SHANK3 (aka PMD) and PTEN.     CFC Starts on 9/1 https://curesyngap1.org/events/fundraisers/combined-federal-campaign-2025/  

Save Money On Your Blood Pressure Monitor.Why Wrist Blood Pressure Monitors Could  Be Dangerous. (Watch Before You Buy!).Welcome to the Hypertension Resistant to Treatment Podcast, the #1 Hypertension Podcast in the world, with listeners from more than 152 countries who depend on our content. We are your primary resource for obtaining straightforward, practical, evidence-based information about high blood pressure management, regardless of your situation as a patient, healthcare provider, or family member. High blood pressure isn't always simple. The condition known as resistant hypertension affects many people who have high blood pressure that does not respond to medication or lifestyle changes. The medical field identifies treatment-resistant hypertension as a demanding yet vital medical condition that doctors encounter in their practice. The Hypertension Resistant to Treatment Podcast, website, and YouTube channel highlight the most challenging cases because these individuals have attempted multiple solutions without achieving any resolution. This podcast is here for them, but also for anyone touched by high blood pressure. Whether you're just starting your journey with prehypertension, you're living with long-standing hypertension, or you're a provider searching for better strategies to help your patients.The right place exists for those seeking answers, motivation, and success tools. The podcast Hypertension Resistant to Treatment presents blood pressure information in an easy-to-understand format that helps people control their condition. The Hypertension Resistant to Treatment podcast is hosted by Dr. Tonya Breaux-Shropshire, PhD, DNP, MPH, FNP-BC. Pubmed, Research Gate, UAB Alumni, and Research SymposiumRecommended models: click hereSend us a text Support the showSupport the podcast by subscribing using this link: click here. We appreciate your support, thank you! Log your blood pressure and share with your provider (click here). Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research.Royalty-free music: Turn on My Swag 2 Epidemic Sound****Disclaimer: This podcast is for educational purposes only and is not medical advice. Always consult your own healthcare provider about your health. The views shared are those of the host and guests, and do not represent any other organization.”

How People Are Lowering Their Blood Pressure Naturally.Featuring Mark Lucus (patient), Dr. Joseph Marek (Cardiologist & Hypertension Specialist, IL), and Dr. Henry Black (Former President of the American Society of Hypertension).Welcome to the Hypertension Resistant to Treatment Podcast, the #1 Hypertension Podcast in the world, with listeners from more than 152 countries who depend on our content. We are your primary resource for obtaining straightforward, practical, evidence-based information about high blood pressure management, regardless of your situation as a patient, healthcare provider, or family member. High blood pressure isn't always simple. The condition known as resistant hypertension affects many people who have high blood pressure that does not respond to medication or lifestyle changes. The medical field identifies treatment-resistant hypertension as a demanding yet vital medical condition that doctors encounter in their practice. The Hypertension Resistant to Treatment Podcast, website, and YouTube channel highlight the most challenging cases because these individuals have attempted multiple solutions without achieving any resolution. This podcast is here for them, but also for anyone touched by high blood pressure. Whether you're just starting your journey with prehypertension, you're living with long-standing hypertension, or you're a provider searching for better strategies to help your patients.The right place exists for those seeking answers, motivation, and success tools. The podcast Hypertension Resistant to Treatment presents blood pressure information in an easy-to-understand format that helps people control their condition. The Hypertension Resistant to Treatment podcast is hosted by Dr. Tonya Breaux-Shropshire, PhD, DNP, MPH, FNP-BC. Pubmed, Research Gate, UAB Alumni, and Research SymposiumSend us a text Support the showSupport the podcast by subscribing using this link: click here. We appreciate your support, thank you! Log your blood pressure and share with your provider (click here). Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research.Royalty-free music: Turn on My Swag 2 Epidemic Sound****Disclaimer: This podcast is for educational purposes only and is not medical advice. Always consult your own healthcare provider about your health. The views shared are those of the host and guests, and do not represent any other organization.”

Friday, August 22nd, 2025. Week 34. The 5th Annual Gala is happening now!  https://www.linkedin.com/posts/curesyngap1_syngap1-curesyngap1-galaforsyngap1-activity-7363593302312402944-W_TZ cureSYNGAP1.org/Gala5   Sad to miss it?  Join us in Boston or South Carolina. Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25 Scramble for SYNGAP October 4, 2025 - Greer, SC cureSYNGAP1.org/Scramble   Stoke Therapeutics indicates they will have a target for SYNGAP-1 in 2026! https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-reports-second-quarter-2025-financial-results 12 Aug 2025 “Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP-1 in 2026. SYNGAP-1 is a severe and rare genetic neurodevelopmental disease.”   Just over 20 FDA approved Oligos and siRNAs today.  We are still so early. https://www.advancingrna.com/doc/moving-beyond-solid-phase-synthesis-the-momentum-of-oligonucleotide-manufacturing-0001   Congrats to Monica E. & Grann Therapeutics, seeing a child dosed for the first time with a novel medicine was remarkable. https://www.grannpharma.com/press-releases The SYNGAP1 Village: How Extended Family Can Provide Vital Support https://curesyngap1.org/blog/syngap1-village-extended-family-can-provide-support/   Here's a fun topic to discuss with your family, brain donation.  https://www.autismbrainnet.org/ 55yo with Dravet, lots of insights, Brava to Dr. Andrade and team! https://onlinelibrary.wiley.com/doi/10.1111/epi.18613   SRF joins with CHOP, Wistar and other Philly-area research institutions with a letter to urge legislators to reject NIH cuts. 8/20/25 Letter can be viewed in SRF Public-facing drive  https://drive.google.com/file/d/1HHmCAuRYAQxb_1DtMtkQTz3H8__g9zKq/view?usp=drive_link Philadelphia Inquirer picked up the story 8/20/25  https://www.inquirer.com/health/medical-research-institutions-reject-nih-cuts-20250820.html    More on #Elopement: Alarms, Roofs, Resonated.  Keep talking to doctors about this.  Post is up to 139 Votes, percentages little changed,  join the conversation on FB. https://www.facebook.com/groups/syngap/posts/1734514154096968/ #S10e178 - https://www.youtube.com/watch?v=OiRnXxh0wfY    Conference is in 103 Days https://curesyngap1.org/events/conferences/cure-syngap1-conference-2025-hosted-by-srf/   Pubmed is at 38! https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   SHARE BLOOD TO THE SRF BIOBANK AT CB! https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    SOCIAL MATTERS - 4,285 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,420 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,294 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? Next New Family Webinar - Tuesday Sept. 9th, 2025, 5 PM Pacific scheduled! https://curesyngap1.org/resources/webinars/webinar-105-syngap-research-fund-quarterly-webinar-new-syngap1-family-orientation/   Resources https://curesyngap1.org/syngap1-resources-for-newly-diagnosed-families   Podcasts, give all of these a five star review! https://cureSYNGAP1.org/SRFApple   https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917    Episode 179 of #Syngap10  #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Tony (11, M) Story.  Now we sleep with the alarm on every night.   Elopement:  involves leaving a safe or supervised area without permission. poses a risk to the individual's safety. can occur in various settings. is a common behavior in individuals with ASD. Virginie (10, M) Stories and Service Dog.   Single Mom (9, M) heading to the judge and calls me asking for papers.  Here you go…   Let's note that Elopement was masked behind broader buckets and I think this is a miss.  We need to name and discuss this very challenging behavior.   FB Survey.  4 hours.  100+ votes, 100 comments.   https://www.facebook.com/groups/syngap/posts/1734514154096968/ 76% of respondents eloped (35% F, 41% M) 24% didn't (17% F, 7% M)   11 F, no elopement at home - but sometimes tries to elope while at school. C ( has always been an eloper - kid has a sixth sense for when someone leaves the door unlocked C elopes and age 16 years old H 9 girl constantly running away B-7.5 years old Girl - 3 Fourteen. She doesn't anymore, but used to. Not to the degree that other families struggle, but we definitely had to keep an extra close eye/ear. Had bells on all our doors, etc. Did get a call from our neighbor once while I was making dinner saying that S had just walked into her house, that she was safe, and was helping to give their baby a bath. Thankfully they were very good friends and took it in stride. (S was about four at the time.) Boys age 7. He has for awhile Boy, age 8.5. Just started eloping more so recently, in the last year. 11, girl Boy age 15 13 year old girl Girl-3 Ty 10 elopes since he can walk. It's our biggest problem. Boy age 8 but has been doing it for a while Age 7, girl. Boy - 14y/o Boy age 9… he's a track star! Boy age 12, has eloped since he could walk/run. It probably peaked around age 6 and got better with meds. Elopement is less frequent now but scarier now that he's older and higher. Boy 10. Always has wandered and will still now run off knowing he's not suppose to Any chance he gets 13 My boy (22 y/o) always was and is now a master of escape, he can hear if I turn the key in the door, front door has an alarm fitted just in case Boy , 25 the risk is high because he looks typical 25 yo female, requiring alarms, cameras,and specialized door locks.  In a state that says that these measures are unlawful restraint and invasion of privacy   Frazier, 2025. Extremely High finding as a Symptom of SYNGAP1.  See Table 2 of Quantifying neurobehavioral profiles across neurodevelopmental genetic syndromes and idiopathic neurodevelopmental disorders https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16112   McKee, 2025.  Notes the significantly heightened enrichment of Autistic Behavior and Behavioral Abnormality vs. Rett, Angelman or Epilepsy cohorts.  See Figure 2B of Clinical signatures of SYNGAP1-related disorders through data integration. https://www.gimjournal.org/article/S1098-3600(25)00066-8/abstract   Cunnanne, notes impulsivity (which is a euphemism for elopement if I have ever heard one) and has three quotes in Table 1 (see below), but also notes in Figure 2 that both ASD and lack of danger awareness came up in almost every interview.  See SYNGAP1-Related Intellectual Disability: Meaningful Clinical Outcomes and Development of a Disease Concept Model Draft.  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5098346   Impulsivity quotes:   Runs toward streets - “He wouldn't stop himself from running into the road. He climbs things in that house that you're like‘oh my god, how are you going to get out of that?'”   Jumps into pools - “He would walk into a pond. We were at the pool the other day…and he just walked off the edge and just fell into the water and was like… he would have just drowned.”   Runs toward crowds - “She was a bolter. So that was always scary. We had a few scares where you look away for a moment, I mean, we always had somebody with her, but it could be a moment's time and it's like where'd you go, you thought she was right there.”   FUNDRAISING 3 events in 3 states… https://mailchi.mp/curesyngap1.org/3-events-1-mission-support-syngap1-families-this-fall?e=e95ed9a1c4  Gala for SYNGAP1 August 22, 2025 - Farmingdale, NJ cureSYNGAP1.org/Gala5 Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25 Scramble for SYNGAP October 4, 2025 - Greer, SC cureSYNGAP1.org/Scramble   Also, Conference is in 107 Days https://curesyngap1.org/events/conferences/cure-syngap1-conference-2025-hosted-by-srf/   STUDIES - MATTER https://docs.google.com/presentation/d/1yRPHMRY3pXPgbOacDM9Sr906VejdJWsonUWvqRD9VVI/edit?usp=sharing    Pubmed is at 37 (One a week!) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   SHARE BLOOD TO THE SRF BIOBANK AT CB! Read here for more information: https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    SOCIAL MATTERS - 4,283 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,420 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,303 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? Next New Family Webinar - Tuesday Sept. 9th, 2025, 5 PM Pacific scheduled! https://curesyngap1.org/resources/webinars/webinar-105-syngap-research-fund-quarterly-webinar-new-syngap1-family-orientation/   Resources https://curesyngap1.org/syngap1-resources-for-newly-diagnosed-families   Podcasts, give all of these a five star review! https://cureSYNGAP1.org/SRFApple   https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917    Episode 178 of #Syngap10  #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

No longer simply known as that chalky powder gym bros take for bigger muscles…creatine is currently undergoing a significant metamorphosis. Though, what happens during this final stage could forever define the creatine market! While creatine was first discovered in muscle tissue in 1832, it took another 160 years before a new era of sports nutrition was created from the pivotal creatine supplementation human study conducted by Dr. Roger Harris. And after Linford Christie, the Barcelona Olympic Games gold medal winning sprinter at 100 meters, mentioned the powerful effects of creatine supplementation in an August 1992 newspaper article...the first commercial creatine supplement hit retail store shelves a year later and quickly gained popularity and widespread adoption among male athletes and fitness enthusiasts. Though, over the next almost quarter-century…it was a relatively boring growth period for the creatine market, with continued research solidifying the ingredient's effectiveness in muscle strength enhancement. Yet, it's this pupation developmental stage, which creatine has been undergoing lately…that very well could be what leads to substantial change across the marketplace, as the scientific flywheel is still spinning quickly! And that's because while many nutraceutical ingredients were popularized within that shadowy niche of sports nutrition, an ever-growing body of research with positive results has broadened use cases and expanded demographics…making them almost must-have staples for everyone. Nevertheless, researchers proving through studies that this nutraceutical ingredient has more than one purpose…isn't all that commercially impactful when you consider that only a microscopic percentage of the consumer market peruses PubMed frequently. Said another way…when a new creatine study gets published on the Internet, does it make a sales register ring? If you picked up on my adaption of the “tree falls in the forest” philosophical thought experiment, then you might guess where I'm going next…as I believe the final “adult” metamorphic stage will be defined by CPG entrepreneurs translating the evolving scientific flywheel of creatine into business ventures. By leveraging a consumer-centric strategic process of questioning, thinking, and subsequently experimenting across various go-to-market roadmaps…entrepreneurs can (and will) successfully reframe creatine, broaden use cases, and discover many new audiences beyond the gym. Though, the final portion of my latest first principles content will explore a few areas that will undoubtedly drive the future of the creatine market…from branding to formats (i.e. creatine gummies) and broadened use cases (and occasions).

We all want more energy — but what if your fatigue isn't about sleep, diet, or exercise at all? In this solo episode, Darin O'Lien uncovers the invisible drains on your vitality that most people never notice. From blue light to toxic relationships, hidden mold, micro-stress loops, EMF exposure, and even unresolved trauma stored in your body, Darin reveals how your life force is being stolen — and how to take it back. You'll learn the overlooked ways your time, attention, and biology are constantly depleted — and the exact SuperLife Energy Seal Protocol Darin uses to plug those leaks, reclaim his vitality, and live fully charged.     What You'll Learn in This Episode 00:00 – Introduction & Episode Overview Darin introduces the concept of hidden energy leaks and why most fatigue isn't just about lack of sleep. 03:05 – Energy Deposits vs. Withdrawals How every interaction, choice, and environment either builds or depletes your life force. 04:33 – The Overlooked Energy Drains The most common — and invisible — ways energy slips away without your awareness. 06:58 – Blue Light & Circadian Rhythm Disruption The science of how nighttime screen use suppresses melatonin and wrecks your sleep quality. 09:06 – Ultra-Processed Foods & Energy Impact Why “dead calorie” foods cause fatigue and how to build an energy-supportive plate. 11:33 – Hydration & Water Quality Why dehydration is the #1 cause of fatigue, and the importance of filtering and mineralizing your water. 15:06 – Micro-Stress Loops & Mental Background Apps How unresolved thoughts quietly drain your energy — and how to shut them down. 17:28 – Toxic Relationships & Social Friction The measurable toll hostile interactions take on your health and recovery. 19:10 – Indoor Air Quality & Mold Exposure How unseen environmental toxins mimic chronic fatigue symptoms. 21:27 – EMF Exposure & Device Overload The overlooked stressor disrupting your sleep, nervous system, and cellular health. 23:14 – Stillness Breaks & Nature Time The proven stress-relieving effects of short nature “pills” and mindfulness pauses. 25:41 – Past Trauma & Recapitulation How unresolved experiences trap your life force — and the Toltec method to reclaim it. 30:39 – The SuperLife Energy Seal Protocol Darin's complete daily checklist to stop leaks and recharge vitality. 33:08 – Darin's Daily Rituals How he integrates energy-protective practices into his everyday life. 35:33 – Closing Thoughts Why energy isn't something you gain — it's what's left when you stop the leaks.     Thank You to Our Sponsors: Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off     Find More from Darin Olien: Instagram: @darinolienPodcast: superlife.com/podcastsWebsite: superlife.comBook: Fatal Conveniences     Key Takeaway "Energy isn't something you get — it's what remains when you stop the leaks."      Bibliography · Chang AM et al. Evening use of light-emitting eReaders… PNAS, 2015. · Hall KD et al. Ultra-processed diets cause excess calorie intake… Cell Metabolism, 2019. · Ganio MS et al. Mild dehydration impairs vigilance… Br J Nutr, 2011. · McEwen BS. Allostatic load and stress physiology. Ann NY Acad Sci, 1999. · Kiecolt-Glaser JK et al. Hostile behavior slows wound healing… Arch Gen Psychiatry, 2005. · CDC/NIOSH. Health problems in damp buildings. · Satish U et al. CO₂ and decision-making. Environ Health Perspect, 2012. · WHO. Electromagnetic fields and public health. · Hunter MCR et al. Nature pill and stress relief. Front Psychol, 2019. · Levine P. Somatic experiencing and trauma discharge. PubMed, 2012. · · Somatic trauma & release: Levine P. Waking the Tiger; “Trauma creates a permanent imprint… the body can be retrained to discharge it.” (pubmed.ncbi.nlm.nih.gov) · · Recapitulation (Toltec lineage): Ruiz DM. The Four Agreements; narrative recounting as energy reclamation. (Ancestral wisdom, narrative psychology) · · Narrative therapy integration: White M. “Externalizing the problem, reclaiming identity.” (Case-based evidence, therapeutic outcomes) · · (And prior citations as listed—circadian, UPF, hydration, air, mindfulness, social, EMF, stillness—remain intact.)

Dr. Hope Rugo and Dr. Kamaria Lee discuss the prevalence of financial toxicity in cancer care in the United States and globally, focusing on breast cancer, and highlight key interventions to mitigate financial hardship. TRANSCRIPT  Dr. Hope Rugo: Hello, and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm your host, Dr. Hope Rugo. I'm the director of the Women's Cancer Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. Rising healthcare costs are causing financial distress for patients and their families across the globe. Patients with cancer report financial toxicity as a major impediment to their quality of life, and its association with worse outcomes is well documented. Today, we'll be discussing how patients with breast cancer are uniquely at risk for financial toxicity. Joining me for this discussion is Dr. Kamaria Lee, a fourth-year radiation oncology resident and health equity researcher at MD Anderson Cancer Center and a co-author of the recently published article titled, "Financial Toxicity in Breast Cancer: Why Does It Matter, Who Is at Risk, and How Do We Intervene?" Our full disclosures are available in the transcript of this episode.  Dr. Lee, it's great to have you on this podcast. Dr. Kamaria Lee: Hey, Dr. Rugo. Thank you so much for having me. I'm excited to be here today. I also would like to recognize my co-authors, Dr. Alexandru Eniu, Dr. Christopher Booth, Molly MacDonald, and Dr. Fumiko Chino, who worked on this book chapter with me and did a fantastic presentation on the topic at ASCO this past year. Dr. Hope Rugo: Thanks very much. We'll now just jump into the questions. We know that rising medical costs contribute to a growing financial burden on patients, which has [GC1]  [JG2]  been documented to contribute to lower quality-of-life, compromised clinical care, and worse health outcomes. How are patients with breast cancer uniquely at risk for financial toxicity? How does the problem vary within the breast cancer population in terms of age, racial and ethnic groups, and those who have metastatic disease? Dr. Kamaria Lee: Breast cancer patients are uniquely at risk of financial toxicity for several reasons. Three key reasons are that breast cancer often requires multimodal treatment. So this means patients are receiving surgery, many receive systemic therapies, including hormonal therapies, as well as radiation. And so this requires care coordination and multiple visits that can increase costs. Secondly, another key reason that patients with breast cancer are uniquely at risk for financial toxicity is that there's often a long survivorship period that includes long-term care for toxicities and continued follow-ups, and patients might also be involved in activities regarding advocacy, but also physical therapy and mental health appointments during their prolonged survivorship, which can also add costs. And a third key reason that patients with breast cancer are uniquely at risk for financial toxicity is that the patient population is primarily women. And we know that women are more likely to have increased caregiver responsibilities while also potentially working and managing their treatments, and so this is another contributor. Within the breast cancer population, those who are younger and those who are from marginalized racial/ethnic groups and those with metastatic disease have been shown to be at an increased risk. Those who are younger may be more likely to need childcare during treatment if they have kids, or they're more likely to be employed and not yet retired, which can be disrupted while receiving treatment. And those who are racial/ethnic minorities may have increased financial toxicity due to reasons that exist even after controlling for socioeconomic factors. And some of these reasons have been shown to be increased risk of job or income loss or transportation barriers during treatment. And lastly, for those with metastatic breast cancer, there can be ongoing financial distress due to the long-term care that is needed for treatment, and this can include parking, transportation, and medications while managing their metastatic disease. Dr. Hope Rugo: I think it is really important to understand these issues as you just outlined. There has been a lot of focus on financial toxicity research in recent years, and that has led to novel approaches in screening for financial hardship. Can you tell us about the new screening tools and interventions and how you can easily apply that to clinical practice, keeping in mind that people aren't at MD Anderson with a bunch of support and information on this but are in clinical practice and seeing many, many patients a day with lots of different cancers? Dr. Kamaria Lee: You're exactly right that there is incredible nuance needed in understanding how to best screen for financial hardship in different types of practices. There are multiple financial toxicity tools. The most commonly used tool is the Comprehensive Score for Financial Toxicity, also known as the COST tool. In its full form, it's an 11-item survey. There's also a summary question as well. And these questions look at objective and subjective financial burden, and it uses a five-point Likert scale. For example, one question on the full form is, "I know that I have enough money in savings, retirement, or assets to cover the cost of my treatment," and then patients are able to respond "not at all" to "very much" with a threshold score for financial toxicity risk. Of course, as you noted, one critique of having an 11-item survey is that there's limited time in patient encounters with their providers. And so recently, Thom et al validated an abbreviated two-question version of the COST tool. This validation was done in an urban comprehensive cancer center, and it was found to have a high predictive value to the full measure. We note which two questions are specifically pulled from the full measure within the book chapter. And this is one way that it can be easier for clinicians who are in a busier setting to still screen for financial toxicity with fewer questions. I also do recommend that clinicians who know their clinic's workflow the best, work with their team of nurses, financial navigators, and others to best integrate the tool into their workflow. For some, this may mean sending the two-item survey as a portal message so that patients can answer it before consults. Other times, it could mean having it on the tablet that can be done in the clinic waiting room. And so there are different ways that screening can be done, even in a busy setting, and acknowledging that different practices have different amounts of resources and time. Dr. Hope Rugo: And where would people access that easily? I recognize that that information is in your chapter, or your article that's on PubMed that will be linked to this podcast, but it is nice to just know where people could easily access that online. Dr. Kamaria Lee: Yes, and so you should be able to Google ‘the COST measure', and then there is a website that also has the forms as well. So it's also beyond the book chapter, Googling ‘the COST measure', and then online they would be able to find access to the form. Dr. Hope Rugo: And how often would you do that screening? Dr. Kamaria Lee: So, I think it's definitely important that we are as proactive as possible. And so initially, I recommend that the screening happens at the time of diagnosis, and so if it's done through the portal, it can be sent before the initial consult, or again, however, is best in the workflow. So at the time of diagnosis and then at regular intervals, so throughout the treatment process, but then also into the follow-up period as well to best understand if there's still a financial burden even after the treatments have been completed. Dr. Hope Rugo: I wonder if in the metastatic setting, you could do it at the change of treatment, you know, a month after somebody's changed treatment, because people may not be as aware of the financial constraints when they first get prescribed a drug. It's more when you hear back from how much it's going to cost. And leading into that, I think it's, what do you do with this? So, you know, this cost conversation is really important. You're going to be talking to the patient about the cost considerations when you, for example, see that there are financial issues, you're prescribing treatments. How do we implement impactful structured cost conversations with our breast cancer patients, help identify financial issues, and intervene? How do we intervene? I mean, as physicians often we aren't really all that aware, or providers, of how to address the cost. Dr. Kamaria Lee: Yes, I agree fully that another key time when to screen for financial toxicity is at that transition between treatments to best understand where they're at based off of what they've received previously for care, and then to anticipate needs when changing regimens, such as like you said in the metastatic setting. As we're collecting this information, you're right, we screen, we get this information, and what do we do? I do agree that there is a lack of knowledge among us clinicians of how do we manage this information. What is insurance? How do we manage insurance and help patients with insurance concerns? How do we help them navigate out-of-pocket costs or even the indirect costs of transportation? Those are a lot of things that are not covered in-depth in traditional medical training. And so it can be overwhelming for a lot of clinicians, not only due to time limitations in clinic, but also just having those conversations within their visit. And so what I would say, a key thing to note, is that this is another area for multidisciplinary care. So just as we're treating patients in a multidisciplinary way within oncology as we work with our medical oncology, surgical colleagues across the board, it's knowing that this is another area for multidisciplinary care. So the team members include all of the different oncologists, but it also includes team members such as financial counselors and navigators and social workers and even understanding nonprofit partners who we have who have money that can be set aside to help reduce costs for certain different aspects of treatment. Another thing I will note is that most patients with breast cancer often say they do want to have these conversations still with their clinicians. So they do still see a clinician as someone that can weigh in on the costs of their treatment or can weigh in on this other aspect of their care, even if it's not the actual medication or the radiation. And so patients do desire to hear from their clinicians about this topic, and so I think another way to make it feel less overwhelming for clinicians like ourselves is to know that even small conversations are helpful and then being knowledgeable about within your institution or, like I said, outside of it with nonprofits, being aware of who can I refer this patient to for continued follow-up and for more detailed information and resources. Dr. Hope Rugo: Are those the successful interventions? It's really referring to financial navigators? How do people identify? You know, in an academic center, we often will sort of punt this to social workers or our nurse navigators. What about in the community? What's a successful intervention example of mitigating financial toxicity? Dr. Kamaria Lee: I agree completely that the context at which people are practicing is important to note. So as you alluded to, in some bigger systems, we do have financial navigators and this has been seen to be successful in providing applications and assisting with applications for things such as pharmaceutical assistance, insurance applications, discount opportunities.  Another successful intervention are financial toxicity tumor boards, which I acknowledge might not be able to exist everywhere. But where this is possible, multidisciplinary tumor boards that include both doctors and nurses and social workers and any other members of the care team have been able to effectively decrease patients' personal spending on care costs and decrease co-pays through having a dedicated time to discuss concerns as they arise or even proactively. Otherwise, I think in the community, there are other interventions in regards to understanding different aspects of government programs that might be available for patients that are not, you know, limited to an institution, but that are more nationally available, and then again, also having the nonprofit, you know, partnerships to see other resources that patients can have access to.  And then I would also say that the indirect costs are a significant burden for many patients. So by that, I mean even parking costs, transportation, childcare. And so even though those aren't interventions necessarily with someone who is a financial navigator, I would recommend that even if it's a community practice, they discuss ways that they can help offset those indirect costs with patients with parking or if there are ways to help offset transportation costs or at least educate patients on other centers that may be closer to them or they can still receive wonderful care, and then also making sure that patients are able to even have appointments scheduled in ways that are easier for them financially.  So even if someone's receiving care out in the community where there's not a financial navigator, as clinicians or our scheduling teams, sometimes there are options to make sure if a patient wants, visits are more so on one day than throughout the week or many hours apart that can really cause loss of income due to missed work. And so there are also kind of more nuanced interventions that can happen even without a financial navigation system in place. Dr. Hope Rugo: I think that those are really good points and it is interesting when you think about financial toxicity. I mean, we worry a lot when patients can't take the drugs because they can't afford them, but there are obviously many other non-treatment, direct treatment-related issues that come up like the parking, childcare, tolls, you know, having a working car, all those kinds of things, and the unexpected things like school is out or something like that that really play a big role where they don't have alternatives. And I think that if we think about just drug costs, I think those are a big issue in the global setting. And your article did address financial toxicity in the global setting. International financial toxicity rates range from 25% of patients with breast cancer in high-income countries to nearly 80% in low- and middle-income countries or LMICs. You had cited a recent meta-analysis of the global burnout from cancer, and that article found that over half of patients faced catastrophic health expenditures. And of course, I travel internationally and have a lot of colleagues who are working in oncology in many countries, and it is really often kind of shocking from our perspective to see what people can get coverage for and how much they have to pay out-of-pocket and how much that changes, that causes a lot of disparity in access to healthcare options, even those that improve survival. Can you comment on the global impact of this problem? Dr. Kamaria Lee: I am glad that you brought this up for discussion as well. Financial toxicity is something that is a significant global issue. As you mentioned, as high as 80% of patients with breast cancer in low- and middle-income countries have had significant financial toxicity. And it's particularly notable that even when looking at breast cancer compared to other malignancies around the world, the burden appears to be worse. This has been seen even in countries with free universal healthcare. One example is Sri Lanka, where they saw high financial toxicity for their patients with breast cancer, even with this free universal healthcare. But there were also those travel costs and just additional out-of-hospital tests that were not covered. Also, literature in low- and middle-income countries shows that patients might also be borrowing money from their social networks, so from their family and their friends, to help cover their treatment costs, and in some cases, people are making daily food compromises to help offset the cost of their care. So there is a really large burden of financial toxicity generally for cancer globally, but also specifically in breast cancer, it warrants specific discussion. In the meta-analysis that you mentioned, they identified key risk factors of financial toxicity globally that included people who had a larger family size, a lower income, a lack of insurance, longer disease duration, so again, the accumulation of visits and costs and co-pay over time, and those who had multiple treatments. And so in the global setting, there is this significant burden, but then I will also note that there is a lack of literature in low-income countries on financial toxicity. So where we suspect that there is a higher burden and where we need to better understand how it's distributed and what interventions can be applied, especially culturally specific interventions for each country and community, there's less research on this topic. So there is definitely an increased need for research in financial toxicity, particularly in the global setting. Dr. Hope Rugo: Yes, and I think that goes on to how we hope that financial toxicity researchers will have approaches to large-scale multi-institutional interventions to improve financial toxicity. I think this is an enormous challenge, but one of the SWOG organizations has done some great work in this area, and a randomized trial addressing cancer-related financial hardship through the delivery of a proactive financial navigation intervention is one area that SWOG has focused on, which I think is really interesting. Of course, that's going to be US-based, which is how we might find our best paths starting. Do you think that's a good path forward, maybe that being able to provide something like that across institutions that are independent of being a cancer only academic center, or more general academic center, or a community practice? You know, is finding ways to help patients with breast cancer and their families understand and better manage financial aspects of cancer care on a national basis the next approach? Dr. Kamaria Lee: Yes, I agree that that is a good approach, and I think the proactive component is also key. We know that patients that are coming to us with any cancer, but including breast cancer, some of them have already experienced a financial burden or have recently had a job loss before even coming to us and having the added distress of our direct costs and our indirect costs. So I think being proactive when they come to us in regards to the additional burden that their cancer treatments may cause is key to try to get ahead of things as much as we can, knowing that even before they've seen us, there might be many financial concerns that they've been navigating.  I think at the national level, that allows us to try to understand things at what might be a higher level of evidence and make sure that we're able to address this for a diverse cohort of patients. I know that sometimes the enrollment can be challenging at the national level when looking at financial toxicity, as then we're involving many different types of financial navigation partners and programs, and so that can maybe make it more complex to understand the best approaches, but I think that it can be done and can really bring our understanding of important financial toxicity interventions to the next level. And then the benefit to families with the proactive component is just allowing them to feel more informed, which can help decrease anticipation, anxiety related to anticipation, and allow them to help plan things moving forward for themselves and for the whole family. Dr. Hope Rugo: Those are really good points and I wonder, I was just thinking as you were talking, that having some kind of a process where you could attach to the electronic health record, you could click on the financial toxicity survey questions that somebody filled out, and then there would be a drop-down menu for interventions or connecting you to people within your clinic or even more broadly that would be potential approaches to manage that toxicity issue so that it doesn't impact care, you know, that people aren't going to decide not to take their medication or not to come in or not to get their labs because of the cost or the transportation or the home care issues that often are a big problem, even parking, as you pointed out, at the cancer center. And actually, we had a philanthropic donor when I was at UCSF who donated a large sum of money for patient assistance, and it was interesting to then have these sequential meetings with all the stakeholders to try and decide how you would use that money. You need a big program, you need to have a way of assessing the things you can intervene with, which is really tough. In that general vein, you know, what are the governmental, institutional, and provider-level actions that are required to help clinicians do our best to do no financial harm, given the fact that we're prescribing really expensive drugs that require a lot of visits when caring for our patients with breast cancer in the curative and in the metastatic setting? Dr. Kamaria Lee: At the governmental level, there are patient assistant programs that do exist, and I think that those can continue and can become more robust. But I also think one element of those is oftentimes the programs that we have at the government level or even institutional levels might have a lot of paperwork or be harder for people with lower literacy levels to complete. And so I think the government can really try to make sure that the paperwork that is given, within reason, with all the information they need, but that the paperwork can be minimized and that there can be clear instructions, as well as increased health insurance options and, you know, medical debt forgiveness as more broad just overall interventions that are needed. I think additionally, institutions that have clinical trials can help ensure that enrollment can be at geographically diverse locations. Some trials do reimburse for travel costs, of course, but sometimes then patients need the reimbursement sooner than it comes. And so I think there's also those considerations of more so upfront funds for patients involved in clinical trials if they're going to have to travel far to be enrolled in that type of care or trying to, again, make clinical trials more available at diverse locations.  I would also say that it's important that those who design clinical trials use what is known as the “Common Sense Oncology” approach of making sure that they're designed in minimizing the use of outcomes that might have a smaller clinical benefit but may have a high financial toxicity. And that also goes to what providers can do, of understanding what's most important to a particular patient in front of them, what outcomes and what benefit, or you know, how many additional months of progression-free survival or things like that might be important to a particular patient and then also educating them and discussing what the associated financial burden is just so that they have the full picture as they make an informed decision. Dr. Hope Rugo: As much as we know. I mean, I think that that's one of the big challenges is that as we prescribe these expensive drugs and often require multiple visits, even, you know, really outside of the clinical trial setting, trying to balance the benefit versus the financial toxicity can be a huge challenge. And that's a big area, I think, that we still need help with, you know. As we have more drugs approved in the early-stage setting and treatments that could be expensive, oral medications, for example, in our Medicare population where the share of cost may be substantial upfront, you know, with an upfront cost, how do we balance the benefits versus the risk? And I think you make an important point that discussing this individually with patients after we found out what the cost is. I think warning patients about the potential for large out-of-pocket cost and asking them to contact us when they know is one way around this. You know, patients feeling like they're sort of out there with a prescription, a recommendation from their doctor, they're scared of their cancer, and they have this huge share of cost that we didn't know about. That's one challenge, and I don't know if there's any suggestions you have about how one should approach that communication with the patient. Dr. Kamaria Lee: Yes, I think part of it is truly looking at each patient as an individual and asking how much they want to know, right? So we all know that patients, some who want more information, some want less, and so I think one way to approach that is asking them about how much information do they want to know, what is most helpful to them. And then also, knowing that if you're in a well-resourced setting that does have the social workers and financial navigators, also making sure it's integrated in the multidisciplinary setting and so that they know who they can go to for what, but also know that as a clinician, you're always happy for them to bring up their concerns and that if it's something that you're not aware of, that you will connect them to the correct multidisciplinary team members who can accurately provide that additional information. Dr. Hope Rugo: Do you have any other additional comments that you'd like to mention that we haven't covered? I think the idea of a financial toxicity screen with two questions that could be implemented at change of therapy or just periodically throughout the course of treatment would be a really great thing, but I think we do need as much information on potential interventions as possible because that's really what challenges people. It's like finding out information that you can't handle. Your article provides a lot of strategies there, which I think are great and can be discussed on a practice and institutional level and applied. Dr. Kamaria Lee: Yeah, I would just like to thank you for the opportunity to discuss such an important topic within oncology and specifically for our patients with breast cancer. I agree that it can feel overwhelming, both for clinicians and patients, to navigate this topic that many of us are not as familiar with, but I would just say that the area of financial toxicity is continuing to evolve as we gather more information on most successful interventions and that our patients can often inform us on, you know, what interventions are most needed as we see them. And so you can have your thinking about it as you see individual patients of, "This person mentioned this could be more useful to them." And so I think also learning from our patients in this space that can seem overwhelming and that maybe we weren't all trained on in medical school to best understand how to approach it and how to give our patients the best care, not just medically, but also financially. Dr. Hope Rugo: Thank you, Dr. Lee, for sharing your insights with us today. Our listeners will find a link, as I mentioned earlier, to the Ed Book article we discussed today in the transcript of this episode. I think it's very useful, a useful resource, and not just for providers, but for clinic staff overall. I think this can be of great value and help open the discussion as well. Dr. Kamaria Lee: Thank you so much, Dr. Rugo. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at Education Sessions from ASCO meetings and our deep dives into new approaches that are shaping modern oncology. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Kamaria Lee @ lee_kamaria Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx    Dr. Kamaria Lee: No relationships to disclose  

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator). Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing.⚡️ WHAT YOU'LL LEARN:- Why medical affairs and regulatory teams can't rely on ChatGPT alone.- How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing - Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review.- Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant).- What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust.- Real-world use cases: scientific summaries, medical info letters and more.

Today's guest, Amita Sharma, shares her deeply personal experience with perimenopause in the corporate world, the mental health toll it took, and how she turned that struggle into NourishDoc, a global wellness platform for women 40 and over. This award-winning episode of Sh!t That Goes On In Our Heads brings you a powerful, eye-opening conversation about the intersection of menopause, mindfulness, and mental health. With over 2 million downloads, we are proud to be the 2024 People's Choice Podcast Award Winner for Health and the 2024 Women in Podcasting Award Winner for Best Mental Health Podcast. We want to hear from YOU. Drop us a voice message or leave your thoughts at:https://castfeedback.com/67521f0bde0b101c7b10442a Mental Health Quote:"The sooner you embrace yourself, the sooner you start living your truth. Otherwise, you're just wearing a mask." — Amita Sharma What This Episode CoversAmita opens up about the invisible toll of perimenopause, from brain fog and depression to sleep deprivation and lost libido—all while trying to survive in a high-stakes, male-dominated tech career. We explore how mindfulness, acupuncture, holistic nutrition, and boundary-setting became her survival tools, and how that journey became the seed for NourishDoc. This comprehensive wellness platform helps thousands of midlife women worldwide. SEO Keywords:Menopause mental health, perimenopause anxiety, midlife women support, mindfulness for menopause, holistic wellness, mental health for women over 40, Amita Sharma, NourishDoc Meet Our Guest: Amita SharmaA former high-tech executive turned wellness innovator, Amita Sharma is the founder of NourishDoc. Her lived experience as a perimenopausal woman in corporate America ignited a mission to support other women through the mental and physical chaos of midlife. NourishDoc offers integrative, evidence-based programs for women 35+, tackling sexual health, menopause symptoms, mental clarity, and long-term chronic condition prevention. Amita's Links:Website: http://www.nourishdoc.com/Facebook: https://www.facebook.com/Nourishdoc/X (Twitter): https://x.com/nourishdocYouTube: https://www.youtube.com/@nourishdocInstagram: http://www.instagram.com/nourish_docLinkedIn: https://www.linkedin.com/in/amita-sharma-nourishdoc/ Key Takeaways: Perimenopause isn't just hot flashes—it deeply impacts mental health, identity, and daily functioning. Holistic wellness tools, such as yoga, journaling, and red-light therapy, can help restore balance. There's a serious education gap in healthcare—many doctors are not trained to recognize or treat perimenopause. Actionable Tips from Amita: Track your symptoms and advocate for testing—don't wait for your doctor to connect the dots. Start mindfulness and journaling daily to help process changes and center yourself. Explore integrative therapies, such as acupuncture, dietary changes, and vaginal health supplements, to enhance quality of life.   Important Chapters & Timestamps00:00 – Intro & Meet Amita03:00 – From Architecture to High-Tech to Holistic Health07:00 – What Perimenopause Really Feels Like12:00 – Mental Health Impact: Depression, Anxiety & Fog16:00 – Cultural Stigma & Workplace Silence22:00 – Loss of Libido, Intimacy, and Sexual Health28:00 – How NourishDoc Empowers Women35:00 – Systemic Gaps in Women's Healthcare43:00 – Amita's Advice to Her Younger Self References: NourishDoc Research & Programs – http://www.nourishdoc.com/ WHO and NIH studies on menopause-related mental health PubMed clinical research (as referenced by Amita)   Subscribe, Rate, and Review!Love what you heard? Don't forget to subscribe for more bold, unfiltered stories about the real stuff going on in our heads. Please take a moment to rate & review us on your favorite podcast platform or on our website:https://goesoninourheads.net/add-your-podcast-reviews For feedback, stories, or shoutouts, visit:https://castfeedback.com/67521f0bde0b101c7b10442a #MentalHealthPodcast #MentalHealthAwareness #PerimenopauseSupport #MidlifeWomenWellness#MenopauseJourney #NourishDoc #AmitaSharma #Grex #DirtySkittles #MindfulnessHealing#HormoneHealth #WomenOver40 #HolisticMentalHealth #AnxietySupport #BurnoutRecovery#SelfCareTips #PodcastForWomen #ChronicConditionPrevention #Podmatch #HealthEquityForWomen ***************************************************************************If You Need Support, Reach OutIf you or someone you know is facing mental health challenges, please don't hesitate to reach out to a crisis hotline in your area. Remember, it's OK not to be OK—talking to someone can make all the difference.United States: Call or Text 988 — 988lifeline.orgCanada: Call or Text 988 — 988.caWorldwide: Find a HelplineMental Health Resources and Tools: The Help HubStay Connected with G-Rex and Dirty SkittlesOfficial Website: goesoninourheads.netFacebook: @shltthatgoesoninourheadsInstagram: @grex_and_dirtyskittlesLinkedIn: G-Rex and Dirty SkittlesJoin Our Newsletter: Sign Up HereMerch Store: goesoninourheads.shopAudio Editing by NJz Audio

In this episode, we're breaking down the four pillars of wellness: sleep, energy balance, lifestyle habits, and stress management. You'll learn why quality sleep is the foundation for hormone balance and recovery, how to build sustainable energy throughout your day, and simple lifestyle anchors that help you feel more grounded and consistent. We'll also dive into proven tools to manage stress — from breathwork to boundaries — so you can build resilience and stay steady even in busy seasons. Whether you're looking to reset your routine or deepen your wellness habits, this episode will meet you where you are.www.trainmk.com@melissa_kendter

Send us a Text Message (please include your email so we can respond!)Episode 70! In this episode we have a special guest, Wes Ely, join us to talk about A2B or "Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients" by Walsh et al published in JAMA May of 2025. A long discussion but a good one, don't miss this one!Pubmed: https://pubmed.ncbi.nlm.nih.gov/40388916/JAMA: https://jamanetwork.com/journals/jama/article-abstract/2834276Editorial: https://jamanetwork.com/journals/jama/article-abstract/2834277If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

Why do so many digital health startups collapse? Dr. Bernardo Perez-Villa explains how a lack of real market validation derails innovation before it starts. Learn how to perform meaningful primary and secondary market research—from asking the right questions to clinicians to scanning Reddit and PubMed for real-world proof of need.

July 16, 2025. Week 29. What is a natural history study (NHS)?  And why do we care? We care because we haven't done this before, heal those born with disease. Natural history studies, which examine the progression of a disease over time, can be either retrospective or prospective. Retrospective studies analyze existing data, like medical records, while prospective studies collect new data over time. Both types are valuable for understanding a disease's course and informing research and treatment strategies. ⁠NHS are critical for clinical trial design.  Size and Quality matter.  Validated scales are better than PROs regardless of what the current rhetoric is. What's going on now? USA - https://curesyngap1.org/resources/studies/syngap1-ProMMiS/ - 135+ over three sites, some with FOUR visits, and counting - Adding GCP - Collaborating with world class institutions and excellent clinicians at Stanford, Children's Colorado and, of course, CHOP. USA - https://Citizen.Health/partners/srf has almost 300 patients! Retrospective Health Data. USA - https://rare-x.org/syngap1/ is where we collect PROs. Australia - Dr. Sheffer is running a study, talk to her or Dani. Latin America - SYNGAP1 Argentina with others joining. Europe - https://www.patre.info/syngap1/  Key takeaways for Industry SYNGAP1 is well positioned to work with… Vlasskamp and Wiltrout are published, Citizen Health is growing & ProMMiS is truly exceptional – and growing, and Rare-X is collecting eight key PROs.   Additionally, there are significant international efforts in Australia, Latin America & Europe. Census: https://curesyngap1.org/blog/syngap1-census-2025-update-55-in-q2-2025-total-1636/  If you are in industry and thinking about starting another NHS for your asset, please don't.  Please instead partner with existing PAGs and NHS studies in your key geographies to move faster, have bigger N and not waste precious patients time, we need to accelerate drug development not slow it down by diluting patients and clinicians between too many studies. Baseline papers on SYNGAP1: 1998 - Huganir - SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family - https://pubmed.ncbi.nlm.nih.gov/9581761/ 2009 - Michaud - Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation - https://pubmed.ncbi.nlm.nih.gov/19196676/ 2013 - Carvill - Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1 - https://pubmed.ncbi.nlm.nih.gov/23708187/ 2019 - Vlasskamp - SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy - https://pubmed.ncbi.nlm.nih.gov/30541864/ 2023 - Rong - Adult Phenotype of SYNGAP1-DEE - https://pubmed.ncbi.nlm.nih.gov/38045990/ 2024 - Wiltrout - Comprehensive phenotypes of patients with SYNGAP1-related disorder reveals high rates of epilepsy and autism - https://pubmed.ncbi.nlm.nih.gov/38470175/ Pubmed is at 28 (so less than one a week…) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   CURE SYNGAP1 CONNECT https://curesyngap1.org/curesyngap1connect/   SHARE BLOOD TO THE SRF BIOBANK AT CB! Read here for more information: https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    SOCIAL MATTERS - 4,238 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,400 followers with 575 Videos on YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,302 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources      Podcasts, give all of these a five star review! https://cureSYNGAP1.org/SRFApple   https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917    Episode 175 of #Syngap10  #RareDisease #PatientAdvocacy #SYNGAP1 #SynGAP #ProMMiS

Get ready for one of our most meaningful conversations yet. Dr. Chloe sits down with Elizabeth DeLuca—the powerhouse advocate whose late-night PubMed searches, cross-country lab visits, and “help-the-babies” fund-raising campaigns helped push Capsida's CAP-002 gene-therapy program all the way to FDA clearance. We unpack how this first-in-human trial aims to restore the missing STXBP1 protein, why the same technology could leapfrog into other rare epilepsies, and how a mother's promise to her daughter is changing the face of science.Quick linksCapsida CAP-002 press release – details on the FDA-cleared trial and how it works: https://capsida.com/capsida-receives-fda-ind-clearance-for-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy/ capsida.comSTXBP1 Foundation – join the registry, learn about natural-history studies, or donate: https://www.stxbp1disorders.org/ STXBP1 FoundationSupport our mission by shopping the herbal lines that fund this podcast and Remy's ongoing care: • Radical Roots Herbs – whole-plant, spagyric CBD formulas: https://RadicalRootsHerbs.com • Noxi Herbs – modular Chinese-herb system for women's hormones: https://NoxiHerbs.comHeads-up: We speak candidly about seizures, neuro-degeneration, and child loss. Estimated annual mortality for STXBP1 remains ~3 %—every child is one too many—and that stark reality fuels Elizabeth's drive and Dr. Chloe's daily fight for her son, Remy.Listen, share, and stand with the rare-disease community that defines our world.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Resistant starch acts more like fiber than starch—and may offer unique benefits for blood sugar, gut health, and more. In this episode, we break down the different types, where to find them, and how they compare to other sources of fiber.Transcript: https://nutrition-diva.simplecast.com/episodes/resistant-starch-your-questions-answered/transcriptMentioned in this episode: Episode 915, Multi-grain vs whole grainEpisode 560, Fiber 2.0—Fiber's New Science of Health-Boosting BenefitsEpisode 728, Tapping into the many benefits of resistant starchesReferences:Wang, Y., Chen, J., Song, Y.-H., Zhao, R., Xia, L., Chen, Y., Cui, Y.-P., Rao, Z.-Y., Zhou, Y., Zhuang, W., & Wu, X.-T. (2019). Effects of the resistant starch on glucose, insulin, insulin resistance, and lipid parameters in overweight or obese adults: a systematic review and meta-analysis. PubMed. https://pubmed.ncbi.nlm.nih.gov/31168050/Yuan, H. C., Meng, Y., Bai, H., Shen, D. Q., Wan, B. C., & Chen, L. Y. (2018). Meta-analysis indicates that resistant starch lowers serum total cholesterol and low-density cholesterol. PubMed. https://pubmed.ncbi.nlm.nih.gov/29914662/ New to Nutrition Diva? Check out our special Spotify playlist for a collection of the best episodes curated by our team and Monica herself! We've also curated some great playlists on specific episode topics including Diabetes and Gut Health! Also, find a playlist of our bone health series, Stronger Bones at Every Age. Have a nutrition question? Send an email to nutrition@quickanddirtytips.com.Follow Nutrition Diva on Facebook and subscribe to the newsletter for more diet and nutrition tips. Find out about Monica's keynotes and other programs at WellnessWorksHere.comNutrition Diva is a part of the Quick and Dirty Tips podcast network. LINKS:Transcripts: https://nutrition-diva.simplecast.com/episodes/Facebook: https://www.facebook.com/QDTNutrition/Newsletter: https://www.quickanddirtytips.com/nutrition-diva-newsletterWellness Works Here: https://wellnessworkshere.comQuick and Dirty Tips: https://quickanddirtytipscom

It's 2 a.m. The on-call resident's voice is shaky. The CT shows an 18cm abdominal aortic aneurysm with a Type 1B endoleak. There's gas in the sac, fluid in the belly, and the patient has a defibrillator on both sides of his chest. Is it a rupture? A graft infection? An aortoenteric fistula? All of the above? You're the vascular surgeon, what do you do?  This episode dives deep into decision-making when EVAR fails, when infection strikes, and when the patient might not survive a definitive repair. Let's talk about what happens when clinical textbooks meet real-world chaos. Hosts: ·      Christian Hadeed -PGY 4 General Surgery, Brookdale Hospital Medical Center ·      Paul Haser -Division chief, Vascular Surgery, Brookdale Hospital Medical Center ·      Andrew Harrington, Vascular surgery, Brookdale Hospital Medical Center ·      Lucio Flores, Vascular surgery, Brookdale Hospital Medical Center Learning objectives: · Understand the clinical implications and management of late EVAR complications, including Type 1B endoleak and aortoenteric fistula. · Explore the decision-making process in critically ill patients with multiple comorbidities and infected aortic grafts. · Compare endovascular vs open surgical approaches in the setting of infected AAA, and when each is appropriate. · Recognize the role of multidisciplinary collaboration in complex vascular cases. · Discuss the ethical considerations and goals-of-care planning in high-risk, potentially terminal vascular patients. · Highlight the importance of long-term surveillance after EVAR and the consequences of noncompliance. References ·       Karl Sörelius et al.Nationwide Study of the Treatment of Mycotic Abdominal Aortic Aneurysms Comparing Open and Endovascular Repair.Circulation. 2016;134(22):1822–1832. PubMed: https://pubmed.ncbi.nlm.nih.gov/27799273/ pubmed.ncbi.nlm.nih.gov+15pubmed.ncbi.nlm.nih.gov+15researchgate.net+15 ·       PARTNERS Trial (OVER Trial).Outcomes Following Endovascular vs Open Repair of Abdominal Aortic Aneurysm: A Randomized Trial.JAMA. 2009;302(14):1535–1542. PubMed: https://pubmed.ncbi.nlm.nih.gov/19826022/ pubmed.ncbi.nlm.nih.gov+6pubmed.ncbi.nlm.nih.gov+6jamanetwork.com+6 ·       B.T. Müller et al.Mycotic Aneurysms of the Thoracic and Abdominal Aorta and Iliac Arteries: Experience with Anatomic and Extra-anatomic Repair in 33 Cases.J Vasc Surg. 2001;33(1):106–113. PubMed: https://pubmed.ncbi.nlm.nih.gov/11137930/ sciencedirect.com+5pubmed.ncbi.nlm.nih.gov+5periodicos.capes.gov.br+5 ·       Chung‑Dann Kan et al.Outcome after Endovascular Stent Graft Treatment for Mycotic Aortic Aneurysm: A Systematic Review.J Vasc Surg. 2007 Nov;46(5):906–912. PubMed: https://pubmed.ncbi.nlm.nih.gov/17905558/ researchgate.net+15pubmed.ncbi.nlm.nih.gov+15pubmed.ncbi.nlm.nih.gov+15 ·       Hamid Gavali et al.Outcome of Radical Surgical Treatment of Abdominal Aortic Graft and Endograft Infections Comparing Extra‑anatomic Bypass with In Situ Reconstruction: A Nationwide Multicentre Study.Eur J Vasc Endovasc Surg. 2021;62(6):918–926. PubMed: https://pubmed.ncbi.nlm.nih.gov/34782231/ pubmed.ncbi.nlm.nih.gov+6pubmed.ncbi.nlm.nih.gov+6diva-portal.org+6  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

Joint aches. Softer muscles. Saggy skin. Brain fog.  Dealing with these not-so-fun issues in midlife? Trust me, you're not the only one. But… these changes aren't “just a part of getting older”. In this podcast, I'm joined by the brilliant Dr. Greg Kelly, Senior VP of Product Development at Qualia Life and a leader in anti-aging and cellular health, to unpack the powerful concept of cellular senescence, also known as “zombie cells.”  These cells don't die when they should, sticking around to cause inflammation, slow down your metabolism, and accelerate aging in your skin, joints, muscles, and brain.  The good news? You're not powerless! Dr. Kelly shares how senolytics—natural compounds that help your body clear out zombie cells—can dramatically shift how you age, supporting your body's innate ability to regenerate.  If you've been feeling like your body is betraying you, this episode will bring hope and science-backed strategies to help you feel vibrant, clear-headed, and strong again. Tune in now! Gregory Kelly N.D. Dr. Gregory Kelly is a naturopathic physician, the SVP of Product Development at Qualia Life, and the author of the book Shape Shift. He was the editor of the journal Alternative Medicine Review and has been an instructor at the University of Bridgeport in the College of Naturopathic Medicine. Dr. Kelly has published hundreds of articles on natural medicine and nutrition, contributed three chapters to the Textbook of Natural Medicine, and has more than 30 journal articles indexed on PubMed. IN THIS EPISODE Enhancing longevity AND wellness in your later years  What are zombie cells, and how do they contribute to aging?  Main parts of the body impacted by zombie or senescent cells  Senolytics and how they work against zombie cells in the body  Qualia Senolytics and the science and research behind them Top non-negotiable supplements for optimal health  Enhancing women's hormonal and reproductive longevity  How to get Qualia Senolytic NOW at a discounted rate!  QUOTES “As these zombie cells accumulate wherever in our body, our joints, our skin, our brain, our muscle tissues, our fat tissues, they cause both local problems and systemic problems.”  “They scanned a whole bunch of different compounds, both plant extracts and actual medications, and came up with two that, especially when combined together, worked really well to get these zombie cells to finally go through cellular death.” “These people all had some degree of joint discomfort, and what we saw was about a 60% improvement over three dosing cycles. So this seemed like it made a big benefit.” RESOURCES MENTIONED Get your Qualia Life Senolytic at 15% off HERE!  Qualia Life Website   Qualia Life Instagram  Qualia Life YouTube Channel  Pre-order my new book: The Perimenopause Revolution HERE  RELATED EPISODES  #653: Mitochondria, Menopause & Metabolism: The Cellular Secret to More Energy After 40 with Dr. Felice Gersh #649: How To Reverse Your Biological Age + 5 Science-Backed Longevity Tips Every Woman Should Know with Leslie Kenny 640: Unveiling The Essential Role of Minerals For Cellular Energy And Detoxification with Caroline Alan 655: The Hidden Truth About Perimenopause That No One's Talking About (And Why It Changes Everything About How You Age)

Send us a Text Message (please include your email so we can respond!)Episode 68! Today we talk about modes of mechanical ventilation with the first author Dr. Kevin Seitz. This was published in CHEST April of 2025 as "Effect of Ventilator Mode on Ventilator-Free Days in Critically Ill Adults: A Randomized Clinical Trial".Disclaimer, this is stated in the episode but Todd and I are authors on this paper. Please keep that in mind as you enjoy the episode!Pubmed: https://pubmed.ncbi.nlm.nih.gov/40189043/CHEST: https://journal.chestnet.org/article/S0012-3692(25)00417-9/fulltextIf you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

This week on Critical Care Time, we're turning the mic over to you, our brilliant listeners! In this special Q&A episode, Nick and Cyrus read your comments, tackle your toughest clinical questions, and share how your insights have sent them diving back into PubMed, Reddit, and beyond. Whether you're commuting, charting, or on break in the ICU, this episode is packed with practical pearls, literature deep-dives, and the human stories that make critical care so rewarding. Thank you for helping us learn and grow—let's jump right in! Hosted on Acast. See acast.com/privacy for more information.

About the Guest(s): Dr. Chad Woolner Dr. Chad Woolner is a pioneering voice in functional and laser medicine. With years of experience under his belt, Dr. Woolner has emerged as a leading advocate for innovative therapies, particularly in the use of low-level laser treatments. Known for his thought leadership in addressing chronic health issues, he continues to explore and promote safer, science-backed health interventions. Dr. Andrew Wells Dr. Andrew Wells is a prominent expert in the chiropractic field, focusing on creating dialogues around modern health challenges and their solutions. He is known for his deep understanding of health systems and passionate advocacy for reform in the use of medical therapies, especially in pediatric care. Dr. Wells combines evidence-based wisdom with practical approaches to health improvement, aiming to shift public and professional perspectives. Episode Summary: In this compelling episode of "The Laser Light Show," Dr. Chad Woolner and Dr. Andrew Wells analyze the recently published MAHA report that reveals concerning trends in child health in America. The report attributes the growing health crisis to ultra-processed foods, environmental toxins, digital addiction, and the excessive use of medical therapies. Yet the report overlooks promising solutions like low-level laser therapy, which Dr. Woolner and Dr. Wells argue is crucial in reversing these alarming health trends. Join them as they delve into how laser technology can play a pivotal role in health recovery. The discussion leads with an examination of systemic failures but quickly progresses to potential solutions, particularly emphasizing the power of light therapy as an overlooked intervention. The guests discuss historical usage of laser therapies in other countries like Russia, highlighting its as-yet-unrealized potential in the U.S. healthcare system. Through enlightening anecdotes and expert perspectives, they argue for broader adoption and understanding of laser solutions in addressing chronic health issues, not only for the individual but also from a systemic, societal perspective. This episode is a thought-provoking exploration for anyone concerned with the current state and future of healthcare. Key Takeaways: The recent MAHA report signals a dire health crisis among American children, primarily driven by poor nutrition, environmental toxins, excessive screen time, and overreliance on medical interventions. There is a growing divide between traditional healthcare methods and innovative solutions, with laser therapy offering a versatile, effective tool that has not been fully embraced. Low-level laser therapy has over 10,000 peer-reviewed studies attesting to its effectiveness for diverse health concerns, yet it remains sidelined in mainstream American medical practices. Historical examples, such as government-endorsed laser therapy in Russia, underline the therapy's viability and yet-to-be-tapped potential in America. Advocacy for improved dialogue and openness to alternative therapies is necessary to shift current healthcare approaches and foster better health outcomes. Notable Quotes: "A federal report just confirmed what many of us… have been saying for years. We are facing the sickest generation of children in American history." - Dr. Chad Woolner "Some of the MAHA report is like obvious, but some of it… really deserves some attention for once." - Dr. Andrew Wells "We should be able to find some degree of common ground when we're talking about health." - Dr. Chad Woolner "Lasers can do just about, if not everything medicine can do, but better and with less side effects." - Dr. Chad Woolner "The great thing is there's a lot of good things that you can use. The hard thing from a government standpoint is there's a lot of really cool things that you could do for a lot of different health issues." - Dr. Andrew Wells Resources: Low-level Laser Therapy (LLLT) Studies - Search for "low-level laser therapy" on PubMed for extensive scientific research. Riconia Lasers - Explore more about Erchonia and their low-level laser products. To fully understand the predictive insights and detailed analysis regarding the vast potential of laser technologies in healthcare, make sure to listen to the full episode. Stay tuned for more enlightening discussions from the "Laser Light Show," where we continue to push the boundaries of conventional medicine and make meaningful changes to health dialogues worldwide.

Send us a textIn this episode, I explore whether the famed Blue Zones offer genuine insights for longevity or if they're more marketing myth than science, while highlighting what the evidence truly shows about living to 100.We begin by considering how many people actually reach 100. Currently, just 0.03% of Americans are centenarians, though this is expected to quadruple by 2054, with women comprising about 78% of that group (Pew Research). Globally, regions like Hong Kong show higher longevity, where 12.8% of females and 4.4% of males are projected to reach 100 (Nature). This brings us to the question: what might we learn from regions like the Blue Zones?I break down how the Blue Zones concept originated, starting with Sardinia where researchers Pes and Poulain mapped centenarians with blue dots, hence the term Blue Zones. Their 2004 study highlighted clusters of longevity (ScienceDirect). Dan Buettner later popularized these findings through his National Geographic article (Blue Zones PDF) and subsequent books, documentaries, and programs. The Blue Zones promote nine lifestyle habits: daily activity, minimal meat and processed foods, moderate red wine intake, calorie reduction, life purpose, stress reduction, spiritual community involvement, prioritizing friendships, and surrounding oneself with like-minded people.While these recommendations align in part with my six pillars of health—exercise, nutrition, mind-body harmony, sleep, exposure to heat/cold, and social relationships—the Blue Zones overlook critical factors like sleep and heat/cold exposure. Their encouragement of moderate alcohol use also contrasts with emerging evidence on alcohol's risks.I examine critiques of Blue Zone science, including flawed birth records that may inflate longevity claims, as seen historically in the U.S. and Greece  (bioRxiv, UCL). Some regions, like Okinawa and Sardinia, no longer display exceptional longevity, possibly due to regression to the mean or changes in lifestyle (PubMed).I also share a rigorous epidemiologic study tracking 80-year-olds to 100, identifying key predictors like non-smoking, low alcohol use, regular exercise, healthy BMI, and dietary diversity (fruits, vegetables, fish, beans, tea). Those with high lifestyle scores had a 60% greater chance of reaching 100 (JAMA).Ultimately, while Blue Zones have helped popularize valuable lifestyle habits, the science behind their claims is mixed. My six pillars remain grounded in evidence that applies to real-world aging.Takeaways: Focus on proven factors—exercise, balanced nutrition, sleep, mind-body practices, social connections, and thoughtful heat/cold exposure—to enhance both lifespan and healthspan. Be cautious about adopting longevity claims without strong evidence. Remember, while genetics play a larger role at extreme ages, your daily choices still profoundly influence your journey toward living long and well.

The symptoms most horses experience from digestive issues and anxiety tend to cause them lots of discomfort. Fortunately, there is a wonderful plant horse owners can use to manage those conditions. Chamomile is a versatile herb with a wide range of uses for horses. It has a calming energy and a pleasant smell, and horses love it!The Link Between Digestion and Anxiety There is a close connection between digestion and anxiety in horses. Stressful events like separation or fear can trigger digestive issues such as colic or ulcers. Those two systems work in a cycle. So, when one is out of balance, the other often follows. Supporting both systems is the key to breaking that loop.A Holistic Strategy To help a horse heal, the owner must identify whether stress or digestion is the primary issue. Sometimes, calming the nervous system allows the gut to recover, while, in other cases, improving digestion eases emotional strain. Reducing stress even slightly can usually create enough momentum for healing.ChamomileChamomile (Matricaria chamomilla) is a well-known traditional herb with a long history of medicinal use. It has yellow-centered white flowers that are easy to recognize. Chamomile contains beneficial compounds like calcium, magnesium, and flavonoids. Those minerals support the nervous system and reduce muscle tension, which is why chamomile is known for its relaxing and soothing properties.Whole Herbs Work BestChamomile benefits digestion, the nervous system, muscles, immunity, and skin in horses. Its strength lies in its synergy. Due to the interaction of many compounds within it, chamomile provides a broad range of health benefits. Isolating a single ingredient can often reduce its effectiveness and cause side effects, which is why whole herbs are preferable. Targeted UsesChamomile is soothing to the gut and the nervous system and can help reduce inflammation, support immune function, and provide antibacterial effects. Horses with chronic digestive tension or stress often benefit greatly from this herb.Chamomile is especially useful for:Digestive upsets, including colic and crampsMuscle tightness and spasmsNervous tension and anxietyFlavonoids Chamomile is rich in flavonoids, which are antioxidants. Its compounds regulate cell function and boost immunity. A 2022 PubMed study identified 50 different flavonoids in chamomile, including quercetin. Chamomile also has antibacterial, anti-inflammatory, and potential anti-cancer properties.Practical Use and DosageCut and sifted chamomile is ideal for horses, as it stays close to its natural form and has a good shelf life. A typical starting dose is one tablespoon, with the option to increase to two. Most horses enjoy chamomile, and its gentle nature makes it easy to introduce. Chamomile can be used short-term for specific issues or longer-term (three months) for chronic imbalances.Chamomile for Variety Chamomile is a gentle herb that does not have a strong taste. So, even horses without anxiety or digestive issues enjoy chamomile added to their diet for variety. Homeopathic Chamomile (Chamomilla)Chamomile is also available in a homeopathic form, Chamomilla. That remedy often gets used for digestive upsets, nervous tension, and teething-related discomfort. It can be helpful for horses that are easily overwhelmed, hard to soothe, or showing signs of intense emotional distress that is difficult to calm.Final ThoughtsChamomile is a powerful, multi-functional herb. It supports the nervous system, digestion, and musculoskeletal system. Whether used to address chronic conditions or balance the...

It's been a month, in that time we've had a few important webinars, published lots of wonderful content & attended BIO in Boston this week. Thank you Virginie for going to BIO https://www.linkedin.com/posts/virginie-mcnamar_bio2025-theworldcantwait-raredisease-activity-7341849619028430848-I_FD    Ambry was awesome https://www.linkedin.com/posts/graglia_syngap1-ambryknowsgenes-activity-7336183874890231809-Beua    CURE SYNGAP1 CONNECT https://curesyngap1.org/curesyngap1connect/   CAMP4 Update - Hear it from them, in our US or EU Webinar.  US https://curesyngap1.org/resources/webinars/106-srf-us-know-about-asos-before-syngap1-clinical-trials-camp4-case-study/ EU https://curesyngap1.org/resources/webinars/107-srf-eu-know-about-asos-before-syngap1-clinical-trials-camp4-case-study/ Amlexanox and Cool Science Amlexanox (Repurposed Readthrough Drug) https://curesyngap1.org/resources/webinars/webinar-108-fortuity-pharma-repurposing-nonsense-mutations/ Cool Science https://curesyngap1.org/resources/webinars/webinar-109-linking-syngap1-and-human-specific-genes-srgap2b-c-that-control-the-tempo-of-synaptic-development/ Inaugural New Family Webinar Saturday June 28th, 2025, 9 AM Pacific https://curesyngap1.org/resources/webinars/syngap-research-fund-quarterly-webinar-new-syngap1-family-orientation/  Tuesday Sept. 9th, 2025, 5 PM Pacific also already scheduled! https://curesyngap1.org/resources/webinars/webinar-105-syngap-research-fund-quarterly-webinar-new-syngap1-family-orientation/   STUDIES - MATTER  ORTAS (need many, 27 signed up, 8 completed.) https://curesyngap1.org/resources/studies/ortas-observer-reported-toileting-abilities-survey/  BEACON (need 7) https://curesyngap1.org/resources/webinars/98-dreem-eeg-headband-to-assess-sleep-eeg-biomarkers-in-syngap1/   “Dear Families, This is a brief update on the Communication abilities in Children with Genetic Conditions study. The Communication abilities in Children with Genetic Conditions study collected parent-reported data on communication ability from 113 families and direct speech and language data from 33 children. Data collection has now closed and research reports are in preparation for the three most successfully recruited conditions; KBG syndrome, SYNGAP1-related disorder, and differences in MED13L. While the study was initially open to a wider group of single-gene conditions, it was only possible to recruit full data sets and large enough samples to produce high quality research reports for these three conditions. While not all of the data collected from families will be included in the research publications, all of the data provided by families has been extremely valuable to the study. Where permission has been given, anonymised data will serve as valuable pilot data to support future funding applications for research on relevant gene conditions. We thank all families for their valued time and participation in the project. Further updates will share our research reports as they become available. With best wishes, Harriet and the Communication abilities in Children with Genetic Conditions study team.”   PRESS  JJ in MD https://www.linkedin.com/posts/curesyngap1_syngap1-curesyngap1-activity-7331703029949267969-7AeK/  Stories #34 with Jo Ashline https://curesyngap1.org/podcasts/syngap1-stories/  Warriors Santiago, Axel and Issac! https://curesyngap1.org/syngap-warriors/  Cafe SYNGAP1 with Dina from NY https://curesyngap1.org/podcasts/cafe-syngap1/dina/  NL45 https://mailchi.mp/curesyngap1.org/make-a-splash-for-syngap1-awareness-45   FUNDRAISING Sprint Blog is Epic https://curesyngap1.org/blog/sprint4syngap-raises-over-200k-for-syngap1-in-5th-annual-fundraiser/ MDBR just happened Four team members raised $15,795 so far. Thanks to Heather Mestemaker, Justin Albrecht, Aaron Harding, and Alicia Harrison. https://cureSYNGAP1.org/MDBR Harper $5k match! https://donate.curesyngap1.org/campaign/694764/donate Liam https://donate.curesyngap1.org/campaign/696438/donate Story https://donate.curesyngap1.org/campaign/695981/donate   Thank you for your support, still matching! https://donate.curesyngap1.org/campaign/693597/donate   Pubmed is at 24 (so less than one a week…) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   Harrison paper on early exons and inherited mutations is great… https://www.eurekalert.org/news-releases/1088068    Cunnane DCM is out and Ingo noticed! https://epilepsygenetics.blog/2025/06/20/revisiting-syngap1-through-a-disease-concept-model/  She spoke at SRF Conference https://www.youtube.com/watch?v=nXagMfYh9VA    SHARE BLOOD TO THE SRF BIOBANK AT CB! Read here for more information: https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    SOCIAL MATTERS - 4,185 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,380 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,314 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources      Podcasts, give all of these a five star review! https://cureSYNGAP1.org/SRFApple   https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917    Episode 173 of #Syngap10  #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Send us a Text Message (please include your email so we can respond!)Episode 66! Today we talk about Acute Chest Syndrome in Sickle Cell Disease with one of our favorite hematologists, Benjamin Tillman! We base our discussion around the TASC trial or "Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease" published by Dessap et al in AJRCCM April of 2025.Pubmed: https://pubmed.ncbi.nlm.nih.gov/40209087/AJRCCM: https://www.atsjournals.org/doi/10.1164/rccm.202409-1727OCIf you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

Chris Mirabile's journey into health and longevity began with a preteen's desire to impress girls during school fitness tests—but quickly evolved into something deeper. By age 12, Chris was reading Men's Health, refining his diet, and obsessing over performance, though he later realized much of his early approach to health was misguided. At 16, his life took a dramatic turn when he suffered a seizure during a school field trip and was diagnosed with a large brain tumor. Emergency brain surgery saved his life, but the experience left a lasting impression, igniting a relentless drive to understand human biology and wellness. ⁣ Though he studied finance and entrepreneurship at NYU, Chris immersed himself in scientific research, especially in bio-gerontology—the biology of aging. Long before it was a buzzword, he was poring over PubMed studies, using genetic testing tools, and analyzing his own DNA to uncover predispositions that might have contributed to his tumor. After early success and eventual failure with a social media startup, Chris doubled down on his passion for health optimization. He founded Novos, a company dedicated to slowing the aging process through science-backed supplements and nutrition, collaborating with researchers from institutions like Harvard, MIT, and the Salk Institute. ⁣ Today, Chris combines rigorous science with real-world application. He launched NovoScore, a daily supplement targeting all 12 known mechanisms of aging, and developed a science-forward meal replacement bar that emphasizes longevity-promoting ingredients over trendy marketing. Through Novos and his personal platform SlowMyAge, Chris educates others on optimizing biological age, drawing from cutting-edge research in omics sciences and data-driven health tracking. With over 10 million supplement doses taken and partnerships expanding, Chris's mission is clear: to empower people to live longer, healthier, and more vibrant lives through informed, evidence-based choices.

In this episode of The Moss Report, Ben Moss sits down with Dr. Ralph Moss to explore the real-world pros and cons of using artificial intelligence in cancer research and care. From AI-generated health advice to PubMed citations that don't exist, this honest conversation covers what AI tools are getting right—and where they can dangerously mislead. Dr. Moss shares the results of his own AI test across five major platforms, exposing their strengths and surprising failures. Whether you're a cancer patient, caregiver, or simply curious about how AI is shaping the future of medicine, this episode is essential listening. Links and Resources:

Send us a textAnswer a few questions to help me improve this podcast here.We all want to live long and well—but how do we determine how many good years we have ahead?In this episode of Live Long and Well with Dr. Bobby, we explore how to estimate both our total lifespan and the number of years we can expect to remain active and pain-free. Dr. Bobby reflects on personal experiences, emerging science, and time-tested frameworks to help you reframe your health trajectory with clarity and motivation. While we may not find exact answers, the tools and thought experiments shared in this conversation can shape the way we live now—and influence how we plan for the future.We begin with why this topic matters, touching on personal stories of loss, aging milestones, and medical advancements. Then we move into three frameworks: how many years you might live (using tools from actuarial tables to cardiovascular risk calculators), how many of those years might be "good," and the wildcard of unpredictable events.The simplest predictor comes from actuarial life tables, which estimate life expectancy by age and sex. A 55-year-old man today might expect to live to 79; a woman to 82. More advanced tools include the Framingham Risk Score, which factors in cholesterol, blood pressure, smoking status, and diabetes to estimate 10-year cardiovascular risk. Research suggests that sharing these risk scores can lead to behavior changes, as shown in this meta-analysis of 28 studies and preliminary evidence of outcome improvements.On the genetics side, polygenic risk scores offer a glimpse into inherited risks, though they remain research tools for now (Nature study). More accessible are tests for specific genes like APOE4, which increases the risk of dementia (PubMed).Beyond numbers, simple physical tests can offer insight. The Brazilian sit-stand test links mobility with mortality risk: fewer than 8 points doubles your six-year mortality risk. Grip strength, too, is a strong predictor of all-cause mortality across 17 countries (PubMed).While biologic clocks based on DNA methylation are generating buzz, their utility remains limited due to variability between samples and testing methods (Nature Communications).When it comes to estimating “good” years—those lived free from major pain or disability—the data are sparse. Some disease-specific tools (e.g., for MS or dementia progression) exist, but there's no universal actuarial equivalent. However, we know muscle mass and aerobic capacity decline predictably with age—1–2% muscle loss per year and a 10% drop in aerobic fitness per decade (OUP Journal). Predicting your future function can begin with assessing how far you can walk, whether stairs leave you breathless, or how your weight and strength compare to a decade ago.Finally, we can't forget unpredictable events: the odds of a serious fall increase significantly after 65, and vision or hearing loss multiplies that risk (NCOA). Building physical resilience now can reduce these odds—see

Is soy actually good for us? Have we been lied to about soy and phytoestrogens?Today I'm sharing some shocking studies on the health benefits of soy and other foods containing phytoestrogens. Soy may not be for everyone—including me (I share why in this episode)—however, it may actually help several women (and men!) in different ways. Here's what the science says… PLUS… foods that contain phytoestrogens beyond soy. STUDIES: This PubMed study found that Asian-Americans who ate tofu had a reduced risk of developing breast cancer. The more tofu they ate, the lower their risk. http://www.ncbi.nlm.nih.gov/pubmed/8922298  Here are 11 PubMed studies highlighting how soy benefits our bones: http://www.ncbi.nlm.nih.gov/pubmed/19367115 http://www.ncbi.nlm.nih.gov/pubmed/11095177 http://www.ncbi.nlm.nih.gov/pubmed/16763748 http://www.ncbi.nlm.nih.gov/pubmed/14557449 http://www.ncbi.nlm.nih.gov/pubmed/12920508 http://www.ncbi.nlm.nih.gov/pubmed/15018488 http://www.ncbi.nlm.nih.gov/pubmed/10757817 http://www.ncbi.nlm.nih.gov/pubmed/15702593 http://www.ncbi.nlm.nih.gov/pubmed/10479216 http://www.ncbi.nlm.nih.gov/pubmed/15309425 http://www.ncbi.nlm.nih.gov/pubmed/10966908 It appears that just taking a daily pill containing the isoflavone genistein may be enough to reap some of soy's bone density benefits:http://www.ncbi.nlm.nih.gov/pubmed/17577003 People in Asia consume much, much, much more soy than those in the West:http://www.smart-publications.com/cancer/daidzein.php Interestingly, men may benefit slightly more than women from eating foods rich in phytoestrogens. These compounds are linked to reduced risks of cancer, cardiovascular disease, cerebrovascular disease, and several other conditions: http://jama.ama-assn.org/cgi/content-nw/full/294/12/1493/JOC50096T5 http://jn.nutrition.org/cgi/content/full/136/12/3046 http://content.onlinejacc.org/cgi/content/full/35/6/1403 As always, if you have any questions for the show please email us at digestthispod@gmail.com.  And if you like this show, please share it, rate it, review it and subscribe to it on your favorite podcast app.  Sponsored By: Armra | Use code DIGEST for 15% off at tryarmra.com/digest  Fatty15 | For 15% off the starter kit go to fatty15.com/digest Bethany's Pantry | Go to bethanyspantry.com and use code PODCAST10 for 10$  Check Out Bethany: Bethany's Instagram: @lilsipper YouTube Bethany's Website Discounts & My Favorite Products My Digestive Support Protein Powder Gut Reset Book  Get my Newsletters (Friday Finds)

Methylene blue is widely marketed over the counter to the general public as well as to the natural health, health freedom, and freedom communities, often on the internet. It is flooding America.   Some sellers are touting methylene blue as a “miracle” tonic that improves “cognitive function”1 and boosts energy to previously unimagined heights. Some have given live demonstrations on TV and podcasts demonstrating how the oral form hyperactivates some people within 35 minutes of the first dose — a typical stimulant drug rush — which is actually a danger signal for potentially activating them into a dangerous manic episode during future exposures or even more deadly outcomes.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   In reality, methylene blue is a lethal neurotoxin, a poison to the brain. It has the same basic chemical composition and harmful clinical effects as the oldest and most neurotoxic “antidepressants,” the monoamine oxidase inhibitors (MAOIs). It also has similarities to the neurotoxic phenothiazine “antipsychotic” drugs, including the original Thorazine (chlorpromazine), but methylene blue is more stimulating or activating.   Methylene blue is not a miraculous new discovery. It is the opposite. Created in 1876 in a lab — it is the oldest manmade chemical to be used in medicine. But in well over a century, methylene blue has never been FDA-approved for psychiatric purposes. Later, its chemical structure was modified in labs for creating many of the earliest, most neurotoxic psychiatric drugs.   Methylene blue suppresses or destroys forms of the enzyme monoamine oxidase that are used by the brain for controlling or modulating four different powerful neurotransmitters — serotonin, dopamine, norepinephrine, and epinephrine. In short, by crushing monoamine oxidase, methylene blue causes overstimulation of four of the brain's major neurotransmitters, all of which profoundly impact the mind.   After the FDA was created in 1906, methylene blue was grandfathered into the market by the agency as an obscure antidote for methemoglobinemia, but it must be emphasized that the FDA has never tested the safety of methylene blue for any purpose. Furthermore, the FDA, based on its adverse reporting system and scientific reports, has published serious warnings about potentially lethal adverse reactions from methylene blue, especially when combined with numerous other drugs.2   The first MAOIs used as depressants were derived from methylene blue, and they turned out to be so toxic that the first two were quickly taken off the market by the FDA. One caused lethal liver disease, and the other caused hypertensive crises. Methylene blue is known to impair liver function tests and to cause hypertensive crises. Early on, all MAOIs were removed for a while from the international list of approved drugs. Please go to this endnote in my report  for a list of historical and scientific studies about the extraordinary history and the nature of methylene blue and the other MAOIs.3   Psychiatry and the psychopharmaceutical complex are so driven to impose neurotoxins upon our brains ⎯ some MAOI antidepressants remain on the market today. FDA Full Prescribing Information for the existing MAOI antidepressants, readily available online,4 provides quick access to the kinds of adverse effects caused by methylene blue. These FDA documents also provide lists of the foods and of some of the many, many drugs you cannot take with MAOIs, like methylene blue, without risking death from serotonin syndrome or a hypertensive crisis.   Meanwhile, all of America is being made a market for the original mother of them all, methylene blue, without requiring a prescription, with bizarrely distorted claims, and with unlimited supplies handed out as easily as a new caffeinated soda.   All of the three approved MAOIs, as well as methylene blue, carry repeated warnings at the FDA and in the scientific community about causing the two potentially crippling and lethal outcomes, serotonin syndrome and malignant hypertension (see below). These potentially lethal outcomes, as with all MAOIs, become much more serious and higher risk when methylene blue is taken with certain foods such as cheese and bananas, or literally with so many other drugs that it is impossible to memorize them or to keep track of them.   Here is one version of a short summary of the long list of dangerous interactions between MAOIs, including methylene blue, and other drugs and foods, taken from Goodman and Gilman's The Pharmacological Basis of Therapeutics (2018, p. 274):   Monoamine Oxidase Inhibitors   Serotonin syndrome is the most serious drug interaction for the MAOIs (see Adverse Effects). The most common cause of serotonin syndrome in patients taking MAOIs is the accidental coadministration of a SHT reuptake-inhibiting antidepressant or tryptophan. Other serious drug interactions include those with meperidine and tramadol. MAOIs also interact with sympathomimetics such as pseudoephedrine, phenylephrine, oxymetazoline, phenylpropanolamine, and amphetamine; these are commonly found in cold and allergy medication and diet aids and should be avoided by patients taking MAOIs. Likewise, patients on MAOIs must avoid foods containing high levels of tyramine: soy products, dried meats and sausages, dried fruits, home-brewed and tap beers, red wine, pickled or fermented foods, and aged cheeses.   I am presenting this detailed summary in the hope of gaining the immediate attention of people and businesses who are promoting methylene blue and anyone who is unfortunately taking it. Please share this summary or the entire document as widely as possible and with proper attribution.   An extensive article follows, detailing my professional experience in the arena of psychopharmacology. It includes a lengthy scientific analysis with more than two dozen endnotes containing an even greater number of scientific citations.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   End Notes   1 All stimulants from caffeine to Ritalin (methylphenidate) and on to methamphetamine and cocaine, and including MAOIs, can produce subjective feelings of improved concentration or memory, and some short-term studies show a brief improvement. This is caused by obsessive-compulsive mental focusing and is driven by a narrowing of general awareness and judgment.  No FDA-approved stimulants, for example, have been proven to help cognition or academic performance, and all harm the brain long-term.  Here is a study that is negligent in its claims and its lack of warnings about methylene blue that may have encouraged the current epidemic use: https://psychiatryonline.org/doi/full/10.1176/appi.pn.2016.pp8a5 I have researched these issues in multiple scientific papers and books, including Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Psychopharmaceutical Complex, second edition (2008).  For an easily accessible, comprehensive look at stimulant drug effects, also see my free resource center on children and stimulant medications: https://breggin.com/Childrens-Resources-Center   2 Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications | FDA and FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and Drug Safety Podcasts > FDA Drug Safety Podcast for Healthcare Professionals: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications (methylthioninium chloride) and serotonergic psychiatric medications | FDA and much more comprehensive coverage of methylene blue adverse effects with special warnings for professionals can be found at Methylene Blue Monograph for Professionals – Drugs.com   3 Half_a_century_of_antidepressant_drugs_-20151101-21548-vmvosk-libre.pdf. Also see Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed and Methylene Blue in the Treatment of Neuropsychiatric Disorders – PubMed; and Iproniazid | Antidepressant, Monoamine Oxidase Inhibitor & Mental Health | Britannica; Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed; Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today – PubMed. These cover the fascinating history of MAOIs and Methylene Blue.    4 The currently approved MAOI antidepressants are phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldpryl, Emsam, Zelapar)), and isocarboxazid (Marplan).     ______   Learn more about Dr. Peter Breggin's work: https://breggin.com/   See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control   Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/   Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/   “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.”   ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.

00:00 Unpopular hair truths no one talks about but everyoneneeds to hear00:41 Unpopular hair truth #1 “Effortless” is a vibe, not areality02:21 Unpopular hair truth #2 Peri-menopause and menopausecan change your hair. It's not in your head and you're not doing anythingwrong.03:53 Unpopular hair truth #3 Seasonal shedding is normal(esp. in the summer)04:02 The three phases of hair growth05:57 Unpopular hair truth #4 The goal is to LOVE your hairat every age of your life.06:46 Hairstylists walk our clients through each phase oflife07:03 Unpopular hair truth #5 Hair is deeply emotional.08:55 Unpopular hair truth #6 A good shower filter will notsave your $300 color from cheap shampoo10:20 The issue with online product quizzes and AIrecommendations (most women don't know what hair they have)11:30 Unpopular hair truth #7 Only 10% of your hair healthis from what happens in the salon. 90% is what happens at home.13:36 Unpopular hair truth #8 Natural color still needsmaintenance, natural texture still needs effort.15:11 Unpopular hair truth #9 You don't have to follow societalbeauty “rules”DePolo, Jaime. (30 January, 2025). Menopausal Hair Changes. Breastcancer.org. https://www.breastcancer.org/treatment-side-effects/menopause/hair-changesKunz, Michael. (29 April, 2009). Seasonality of hair shedding in healthy women complaining of hair loss. Pubmed. https://pubmed.ncbi.nlm.nih.gov/19407435/10 Hair Care Habits that can Damage Your Hair. American Academy of Dermatology. https://www.aad.org/public/everyday-care/hair-scalp-care/hair/habits-that-damage-hair

Identifying and Evaluating Young Children with Developmental Central Hypotonia: An Overview of Systematic Reviews and ToolsChildren with developmental central hypotonia have reduced muscle tone secondary to non-progressive damage to the brain or brainstem. Children may have transient delays, mild or global functional impairments, and the lack of a clear understanding of this diagnosis makes evaluating appropriate interventions challenging. This overview aimed to systematically describe the best available evidence for tools to identify and evaluate children with developmental central hypotonia aged 2 months to 6 years. A systematic review of systematic reviews or syntheses was conducted with electronic searches in PubMed, Medline, CINAHL, Scopus, Cochrane Database of Systematic Reviews, Google Scholar, and PEDro and supplemented with hand-searching. Methodological quality and risk-of-bias were evaluated, and included reviews and tools were compared and contrasted. Three systematic reviews, an evidence-based clinical assessment algorithm, three measurement protocols, and two additional measurement tools were identified. For children aged 2 months to 2 years, the Hammersmith Infant Neurological Examination has the strongest measurement properties and contains a subset of items that may be useful for quantifying the severity of hypotonia. For children aged 2-6 years, a clinical algorithm and individual tools provide guidance. Further research is required to develop and validate all evaluative tools for children with developmental central hypotonia.

BUFFALO, NY - May 14, 2025 – A new #review paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Relationship between ABO blood group antigens and Rh factor with breast cancer: A systematic review and meta-analysis." A comprehensive study, led by first authors Rahaf Alchazal from Yarmouk University and Khaled J. Zaitoun from Johns Hopkins University School of Medicine and Jordan University of Science and Technology, examined the potential link between blood type and breast cancer. The research team conducted a systematic review and meta-analysis of 29 previously published studies, involving more than 13,000 breast cancer patients and over 717,000 controls. “Researchers searched for studies on breast cancer patients and ABO blood groups across four major databases: PubMed, Scopus, Web of Science, and Google.“ Breast cancer is the most common cancer among women worldwide. Identifying risk factors is vital for early detection and prevention. While many studies have explored lifestyle and genetic causes, this analysis focused on the ABO blood group system. By pooling global data, the researchers found that blood type A was the most common among breast cancer patients and was significantly associated with an 18% increased risk compared to type O. The study did not find a significant association between breast cancer and blood types B, AB, or Rh factor. Although the results do not prove causation, they point to a biological pattern worth further investigation. Blood group antigens are proteins found on the surface of cells, including breast tissue. These molecules may influence how cancer develops and spreads by interacting with the immune system or affecting cell behavior. This meta-analysis is the most extensive review to date on this topic, based on studies conducted across Asia, Europe, Africa, and the Americas. While previous research found unclear conclusions, this large-scale evaluation provides stronger evidence for a possible connection between blood type A and breast cancer risk. Researchers note that regional differences, genetic diversity, and study quality may affect individual results. Nevertheless, the overall trend supports considering blood type A as a potential risk marker. This insight could help shape screening guidelines, encouraging earlier or more frequent checkups for women with this blood type. Further research is needed to understand why blood type A may play a role in cancer development. Future studies may explore genetic mechanisms, immune responses, and other biological pathways. These efforts could lead the way for more personalized cancer prevention and care strategies. DOI - https://doi.org/10.18632/oncotarget.28718 Correspondence to - Khaled J. Zaitoun - kzaitou1@jh.edu Video short - https://www.youtube.com/watch?v=BQFVtreaetI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28718 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, breast cancer, cancer risk factors, blood group antigens, tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Chris Mirabile's journey to achieving a biological age 13.6 years younger than his chronological age is not a tale of luck but of deliberate action and deep scientific understanding. His transformation extends beyond mere youthful appearance. He's aging 31% slower than average.  This remarkable feat is rooted in intense self-education and a disciplined lifestyle geared towards optimizing health at a molecular level. His story began at 16, when a severe seizure led to the discovery and surgical removal of a brain tumor. This life-altering event shifted his focus from basic fitness to a profound understanding of human biology and aging. A Scientific Awakening Chris transitioned from merely wanting to look fit to optimizing his long-term well-being. Utilizing academic databases like PubMed, he educated himself on the science of aging and its biological processes. The "Hallmarks of Aging" paper was a turning point, revealing aging not as inevitable, but as a series of manageable biological processes. This realization drove him to a proactive approach to health, aiming to manage and slow aging. Targeting the 12 Aging Mechanisms Today, Chris's lifestyle and biotechnology company NOVOS are structured around the 12 mechanisms that drive aging. Here's a quick look at how he addresses each: Mitochondrial Dysfunction: Enhanced through exercise and specific nutrients. Cellular Senescence: Reduced via supplements and fasting. Loss of Proteostasis: Improved by autophagy-activating practices. Intercellular Communication: Maintained by limiting inflammation. Genomic Instability: Addressed with hormetic stress like cold exposure. Epigenetic Alterations: Supported with lifestyle changes. Telomere Shortening: Minimized with diet and recovery. Deregulated Nutrient Sensing: Balanced through feeding/fasting cycles. Stem Cell Exhaustion: Preserved with low-inflammation living. Inflammaging: Reduced with anti-inflammatory strategies. Disabled Autophagy: Enhanced by intermittent fasting and polyphenols. Gut Dysbiosis: Improved through diet diversity and probiotics. By targeting these mechanisms, Chris actively works to slow and even reverse biological aging. Lifestyle as Medicine For Chris, lifestyle is the foundation of health optimization. His daily routine reflects the principles he has gleaned from his research. His diet follows a Mediterranean model, emphasizing whole plants, healthy fats, and moderate protein. He integrates periodic fasting to optimize longevity pathways. His exercise regimen is multifaceted, combining resistance training four times a week, cardio three times a week, and daily walking. Sleep is prioritized, with seven to nine hours tracked via the Oura Ring. Stress management is crucial, as well as incorporating journaling, meditation, and reframing challenges as opportunities for growth. He also utilizes specific supplements, such as NOVOS Core, developed from biotech research to support the hallmarks of aging. NOVOS: Measuring and Managing Aging NOVOS embodies Chris's belief in the scientific manageability of aging. The company offers precise formulations like NOVOS Core, which has shown lifespan extension in animal studies, and biological age testing via epigenetic analysis. The NOVOS Life app provides digital guidance, using AI to generate personalized longevity plans and estimate biological age, making longevity accessible and manageable. In this podcast, you'll learn... How Chris Mirabile reduced his biological age by 13.6 years and its importance. The 12 aging mechanisms Chris targets with NOVOS. Practical lifestyle adjustments for longevity, including diet, exercise, and stress management. The role of scientific innovation in managing aging. How to reframe challenges and use adversity for personal growth. EPISODE RESOURCES: Website LinkedIn Instagram xCom

Send us a Text Message (please include your email so we can respond!)Episode 64! We talk more about steroids in severe community acquired pneumonia with "Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial" published in Intensive Care Medicine April of 2025.Pubmed: https://pubmed.ncbi.nlm.nih.gov/40261382/If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

Welcome to Episode 45 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 45 of “The 2 View” – All things toxicology: the intoxicated patient, propranolol overdose and suicide, snake bites, and a special guest. Segment 1 – The intoxicated patient Kaufman J, Fitzpatrick P, Tosif S, et al. Faster clean catch urine collection (Quick-Wee method) from infants: randomised controlled trial. BMJ. The BMJ. Published April 7, 2017. https://www.bmj.com/content/357/bmj.j1341 Kraaijvanger N, Raven W, van Dijken T, Gresnigt F. The PIRATE mnemonic: providing a structured approach in the care for intoxicated patients at the emergency department. Int J Emerg Med. Educational Advances in Emergency Medicine. BMC: Part of Springer Nature. Published March 1, 2024 https://intjem.biomedcentral.com/articles/10.1186/s12245-024-00606-4 Thiessen P. A simple new technique for collecting urine in infants. Thischangedmypractice.com. The University of British Columbia. Faculty of Medicine: This Changed My Practice (TCMP) by UBC CPD. Published November 18, 2015. https://thischangedmypractice.com/new-technique-for-collecting-urine-in-infants/ Van Oyen A, Barney N, Grabinski Z, et al. Urine Toxicology Test for Children With Altered Mental Status. Aap.org. Pediatrics. Case Reports. American Academy of Pediatrics: Dedicated to the Health of All Children. Published October 6, 2023. https://publications.aap.org/pediatrics/article/152/5/e2022060861/194346/Urine-Toxicology-Test-for-Children-With-Altered?autologincheck=redirected Segment 2 – Propranolol overdose and suicide Khalid MM, Galuska MA, Hamilton RJ. Beta-Blocker Toxicity. In: StatPearls. StatPearls Publishing. NIH: National Library of Medicine – National Center for Biotechnology Information. Published July 28, 2023. https://www.ncbi.nlm.nih.gov/books/NBK448097/ Srettabunjong S. Fatal Self-Poisoning With Massive Propranolol Ingestion in a Young Male Physician. Am J Forensic Med Pathol. PubMed®. NIH: National Library of Medicine – National Center for Biotechnology Information. Published September 2017. https://pubmed.ncbi.nlm.nih.gov/28691951/ Segment 3 – Snake bites Rohl S, Meredith M, Anderson, T, et al. Comparing the Use of Crotaline-Polyvalent Immune Fab (Ovine) Versus Observation in Children. Pediatric Emergency Care: Dedicated to the Care of the Ill or Injured Child. Lww.com. Published November 2024. https://journals.lww.com/pec-online/abstract/2024/11000/comparingtheuseofcrotalinepolyvalentimmune.19.aspx Snake bites. Wikem.org. WikiEM. Last edited March 17, 2021. https://wikem.org/wiki/Snake_bites Toxicology resources Goldfrank LR, Flomenbaum NE, Howland MA, et al. Goldfrank's Toxicologic Emergencies. 8th ed. McGraw-Hill Medical; 2006. Katz K, O'Connor A, Amaducci AM. EMRA and ACMT Medical Toxicology Guide: 2nd Edition.; 2022. National Poison Data System. Poisoncenters.org. America's Poison Centers: Treatment, Education, Prevention. Accessed April 9, 2025. https://poisoncenters.org/national-poison-data-system Poison Control: National Capital Poison Center. Poison.org. Accessed April 9, 2025. https://www.poison.org/ Segment 4 – Special guest: Nancy Denke, DNP, ACNP-BC, FNP-BC, FAEN, CEN, CCRN, of Arizona Linkedin.com. Accessed April 9, 2025. https://www.linkedin.com/in/nancy-denke-dnp-acnp-bc-fnp-bc-faen-a62851 Nancy Denke, DNP, ACNP-BC, FNP-BC, FAEN, CEN, CCRN, of Arizona. ENA Hall of Honor. Published July 26, 2024. Accessed April 9, 2025. https://hall-of-honor.org/nancy-denke PodBean Development. Talking Toxicology: A Recipe for Disaster (Nancy Denke). BCEN & Friends Podcast. PodBean. Published March 7, 2023. https://bcenandfriends.podbean.com/e/talking-toxicology-a-recipe-for-disaster-nancy-denke/ *Recurring Sources * Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!

CME professionals, medical writers, educators, and researchers - what would you do if PubMed suddenly became less accessible? You depend on this critical resource daily to find evidence-based information that powers your work. But recent funding uncertainties at the NIH have raised questions about its future. You need consistent, reliable access to quality biomedical research to meet deadlines and maintain credibility, but navigating alternatives can feel overwhelming. Where would you even begin if your go-to resource is compromised? Today's episode is your insurance policy. My conversation with medical librarian Rachel Wedeward MLIS, AHIP reveals not only why PubMed matters, but also provides you with practical alternatives, including a downloadable resource sheet, and evaluation strategies to ensure you'll never be left without the research you need - no matter what happens. In this episode, you'll discover: The remarkable infrastructure behind PubMed's indexing system that makes it an indispensable tool for organizing and accessing biomedical research A comprehensive overview of complementary resources, including European PubMed Central and specialized databases that can enhance your research approach Practical wisdom for evaluating evidence quality Listen now to expand your research toolkit with expert knowledge that will help you confidently navigate the evolving landscape of medical information resources. Connect with Rachel Website LinkedIn

Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️

Joe Cohen's journey to optimal health is a story of self-discovery and a drive to find answers beyond conventional medicine. Struggling with chronic health issues like fatigue, inflammation, and brain fog, Joe took charge of his health by diving into genetics, biomarkers, and biohacking. A Start of Struggle: The Search for Answers Joe's early attempts to seek help from mainstream doctors were unfruitful. Frustrated, he embarked on self-experimentation. He started with lifestyle changes like intermittent fasting and cold plunges, which offered some relief. However, it was when Joe incorporated supplements into his regimen that he began to experience more significant improvements. The Quest for Scientific Answers Determined to understand his body, Joe turned to scientific resources like PubMed and Wikipedia. He discovered that health protocols were not one-size-fits-all. Joe tried various diets, such as veganism and the Bulletproof Diet, but ultimately found success with a carnivore and lectin-free approach. He realized that his body didn't respond well to grains and legumes, leading him to adopt a lectin-avoidance diet early on. The Power of Genetics and Personalized Experimentation Joe realized that understanding his individual biology was key. He learned that genetic factors, such as immune system dominance, played a crucial role in how his body reacted to different foods and supplements. This led to the development of SelfDecode, a platform providing genetic insights for personalized health optimization. He found that genetic testing, combined with lab testing and supplements, offered a holistic approach. Supplementation: The Game Changer For Joe, supplementation became a cornerstone of his biohacking strategy. He believes supplements have had the most significant impact on his health. With over 160 supplements in his daily regimen, Joe emphasizes the importance of understanding which supplements are best for an individual's unique needs. He encourages guided experimentation to find the right mix, considering genetics, biomarkers, and personal health goals. The Future of Biohacking: AI, Genetics, and Longevity Joe envisions a future where breakthroughs in organ replacement and genetic manipulation could significantly extend human lifespan. He also sees AI playing a crucial role in improving genetic research, health recommendations, and biohacking strategies. The Key to Rewiring Your Health Joe Cohen's journey shows that optimizing your health requires scientific inquiry, personalized experimentation, and an open mind toward biohacking tools. By understanding your body deeply and embracing self-experimentation, you can create a health protocol tailored to your unique needs. In this podcast, you'll learn: How Joe took control of his health when conventional medicine failed him. The power of personalized supplements and why they are crucial for optimal health. Why understanding your unique biology and genetics is essential for health optimization. How Joe developed a lectin-free diet before it became mainstream and why it worked for him. Joe's vision for the future of biohacking, including AI and genetic manipulation for longevity.   EPISODE RESOURCES: Website Instagram Youtube  

In this second episode of a three-part series, Drs. Ruth Carrico and Paula Tucker explore the challenges of medical misinformation, its impact on patient care and strategies for navigating the overwhelming flow of health information in today's digital age. The discussion covers the rise of the "infodemic” how misinformation spreads and how nurse practitioners (NPs) can critically evaluate medical literature to ensure evidence-based practice. The hosts share real-world experiences from the COVID-19 pandemic, highlighting the difficulties of adapting to rapidly evolving guidelines while maintaining public trust. They also discuss the role of social determinants of health in the spread of misinformation and provide practical solutions for mitigating misinformation in clinical settings. Key Takeaways: Understanding the Infodemic: Definition: An overload of health-related information — both accurate and inaccurate — spread rapidly via social media, news and professional circles. Impact of COVID-19: Misinformation amplified due to evolving scientific knowledge, political influences and social media algorithms. Role of Trust: Public mistrust in health care institutions and shifting guidelines fueled skepticism. Misinformation Drivers and Consequences: Psychological Factors: Cognitive biases (confirmation bias, authority bias) make individuals more susceptible to misinformation. Technology and Social Media: Algorithm-driven content creates echo chambers where misinformation spreads unchecked. Public Health Outcomes: Misinformation leads to vaccine hesitancy, delayed treatments and preventable deaths. How NPs Can Combat Misinformation: 1. Active Listening: Understand patients' concerns before correcting misinformation. 2. Effective Communication: Use simple, culturally relevant messaging tailored to health literacy levels. 3. Building Resilience: Teach patients how to critically evaluate health information sources. 4. Community Engagement: Collaborate with local leaders and organizations to promote credible information. Evaluating Evidence-Based Information: Use the CRAAP Test (Currency, Relevance, Authority, Accuracy, Purpose) to assess credibility. Trust peer-reviewed sources like CDC, WHO, FDA, Cochrane Reviews and PubMed. Be aware of misleading studies and cherry-picked data used to spread misinformation. Trusted Resources for Patients and Providers: For Clinicians: UpToDate, DynaMed, BMJ Best Practice, Cochrane Reviews. For Patients: MedlinePlus, Mayo Clinic, CDC Vaccine Fact Sheets, American Heart Association. To claim 1.1 contact hours (CH) of continuing education (CE) credit for this program, “Navigating the Infodemic: A Call for Critical Thinking to Optimize Patient Care,” search for this program by the title and complete the posttest and evaluation by entering the participation code provided after listening to the podcast. “This activity is sponsored by an independent medical education grant from Kenvue.” Tool: https://www.aanp.org/practice/clinical-resources-for-nps/clinical-resources-by-therapeutic-area/primary-care Next Episode Preview: In the final episode of this series, Drs. Carrico and Tucker will dive into practical strategies for debunking medical myths, patient-centered communication techniques and choosing the right battles when addressing misinformation.

Wednesday, April 9, 2025 – Week 15   Condolences to the Brimsek family and thank you John & Tobi for all your support.  We just shared an interview with our board member and John's son-in-law, Eric Moulton https://cureSYNGAP1.org/Stories    Trip Report, two crazy days.  Many takeaways.  Trials may be coming soon.  If there is a trail, sign up.  Every time. khuba@jcu.edu    Do the Frazier Study and do the follow-ups!  https://curesyngap1.org/eye2 Global as well.  Australia, UK, Canada, please help.   We are busy too!  DiMe announcement just came out https://www.linkedin.com/posts/curesyngap1_new-project-announcement-children-with-activity-7315615778366537728-c-gU    Census is 1,581!  https://curesyngap1.org/blog/syngap1-census-2025-update-q1/   Impact report has a webinar! https://cureSYNGAP1.org/Impact    Both featured in Newsletter #44 - https://cureSYNGAP1.org/NL44   Monday 4/14 we have a webinar - Natural History & Clinical Trial Readiness - with Dr. McKee https://cureSYNGAP1.org/Jill    We have one space available in Colorado on May 20, 2025, email Lauren@curesyngap1.org to sign up.   Other blog about the CB Roadshow, please join us there https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/   And the Polish Community speaking out about ASO trials: https://curesyngap1.org/blog/aso-choice-for-hope-syngap1-voices-from-poland/   #Sprint4Syngap 2025 is in one month! Start or join a team and fundraise! https://curesyngap1.org/sprint25 look at these faces, $66,383 https://www.youtube.com/watch?v=IW7owIsdjss   Bowie - Our funding goes far: https://www.eurekalert.org/news-releases/1078836 remember in July 2022 https://www.eurekalert.org/news-releases/960181    Also see this from CZI, featuring SYNGAP1 in Dr. Willsey's work https://www.czbiohub.org/life-science/unlocking-biology-autism/   PubMed is at 17 YTD, 324 in total (trending to 52+, but I'm not as confident) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.1998-2025&timeline=expanded&sort=date&sort_order=asc   VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/   SOCIAL MATTERS - 3,996 LinkedIn.  https://www.linkedin.com/company/curesyngap1/ - 1,334 YouTube.  https://www.youtube.com/@CureSYNGAP1  - 11,391 Twitter https://twitter.com/cureSYNGAP1 - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources    Podcasts, give all of these a five star review! https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917   Episode 168 of #Syngap10  #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Welcome to the SYNC Your Life podcast episode #317! On this podcast, we will be diving into all things women's hormones to help you learn how to live in alignment with your female physiology. Too many women are living with their check engine lights flashing. You know you feel “off” but no matter what you do, you can't seem to have the energy, or lose the weight, or feel your best. This podcast exists to shed light on the important topic of healthy hormones and cycle syncing, to help you gain maximum energy in your life.  In today's episode, I dive into whether or not there is a "faster way" to losing weight. I dive into common questions I get regarding carb cycling, fasting, and more, and whether those things are good for female physiology.  I reference Dr. Stacy Sims and her research on this in multiple instances. You can learn more via Sims' blog found here. Dr. Sims also has several articles published via PubMed on the subject of female athletes. If you're a woman who trains, you're an athlete, so this research is most relevant! I've linked only a few research articles here: Low Energy Availability in Women Female Specific Nutrition Nutritional Concerns for Female Athletes To learn more about the SYNC™ course and fitness program, click here. To learn more about virtual consults with our resident hormone health doctor, click here. If you feel like something is “off” with your hormones, check out the FREE hormone imbalance quiz at sync.jennyswisher.com.  To learn more about Hugh & Grace and my favorite 3rd party tested endocrine disruption free products, including skin care, home care, and detox support, click here. To learn more about the SYNC and Hugh & Grace dual income opportunity, click here. Let's be friends outside of the podcast! Send me a message or schedule a call so I can get to know you better. You can reach out at https://jennyswisher.com/contact-2/. Enjoy the show! Episode Webpage: jennyswisher.com/podcast

The pervasive presence of microplastics and environmental toxins in our daily lives poses a growing threat to human health, with impacts ranging from hormonal disruption and metabolic dysfunction to immune system compromise and chronic inflammation. These contaminants, found in food packaging, water supplies, personal care products, and even the air we breathe, accumulate in the body and contribute to the rise in chronic diseases such as obesity, diabetes, cancer, and autoimmune conditions. Understanding their far-reaching effects is essential, but the good news is that the body has powerful detoxification mechanisms that, when properly supported through dietary choices, lifestyle adjustments, and targeted supplementation, can help mitigate their damage.  In this episode, I discuss, along with toxin-expert Dr. Joseph Pizzorno, why we need to take action to reduce toxin exposures, reverse existing damage, and build a foundation for long-term well-being. Dr. Joseph Pizzorno is a transformational leader in medicine. Through half a century of work, he has helped establish and advance the academic, scientific, and clinical protocols for natural, functional, integrative, and environmental medicine. As founding president of Bastyr University in 1978, he coined the term “science-based natural medicine” and led Bastyr to become the first-ever accredited institution in the field. He has set worldwide standards of practice by authoring or co-authoring six textbooks for doctors, including the Textbook of Natural Medicine (over 100,000 copies in 4 languages across 5 editions) and Clinical Environmental Medicine. He is Editor-in-Chief of PubMed-indexed IMCJ—the most widely read, peer-reviewed journal in the field (25,000 copies each issue). He is a founding member of the Board of Directors of the Institute for Functional Medicine, where he served three terms as Chair. A licensed naturopathic physician, educator, researcher, and expert spokesman, he is also the author or co-author of eight consumer books (most recent, Healthy Bones, Healthy You! with his wife Lara).  This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Microplastics: What They Are, Why They are Dangerous, and How to Protect Yourself Environmental Toxins: How To Eliminate the Silent Killers with Dr. Joseph Pizzorno How To Reduce Your Environmental Toxin Exposure